| Home | Log In | Register | Our Services | My Account | Contact | Help |
You are NOT currently logged in
Register now or login to post to this thread.
ANGLE - Share price 86p broker target 165p - SIGNIFICANTLY UNDERVALUED (AGL)
thorhildur - 29 Jan 2006 11:45
Two new broker notes out last week on this one -
Collins Stewart gives a target valuation for the combined entity of 26 million or 156p per share
Edison Investments embedded valuation is 31m - Indicating a 100% gain in share price from current levels. They suggest that using the current embedded valuation model, the current value of Angles six non-exited ventures is only 5.5m - suggesting Angle to be SIGNIFICANTLY UNDERVALUED
Have a look
Collins Stewart gives a target valuation for the combined entity of 26 million or 156p per share
Edison Investments embedded valuation is 31m - Indicating a 100% gain in share price from current levels. They suggest that using the current embedded valuation model, the current value of Angles six non-exited ventures is only 5.5m - suggesting Angle to be SIGNIFICANTLY UNDERVALUED
Have a look
thorhildur - 29 Jan 2006 14:15 - 2 of 195
Worth reading the new broker notes if you have them.
Edison note is listed on their website.
A good play as you say with its 25% of Provexis (PXS) - note the recent rise of PXS since the publication of results.
62m shares (24.8% of companys 250m is issue) based at mid price on Friday (11.625p) adds close to a 1m gain to the 6.3m mentioned in the results...
Share price shows shows the start of a reversal -
The last two candlesticks formed a Bullish Harami Pattern . This is a bullish reversal pattern that marks a potential change in trend.
Edison note is listed on their website.
A good play as you say with its 25% of Provexis (PXS) - note the recent rise of PXS since the publication of results.
62m shares (24.8% of companys 250m is issue) based at mid price on Friday (11.625p) adds close to a 1m gain to the 6.3m mentioned in the results...
Share price shows shows the start of a reversal -
The last two candlesticks formed a Bullish Harami Pattern . This is a bullish reversal pattern that marks a potential change in trend.
thorhildur - 31 Jan 2006 20:56 - 3 of 195
Edison Research note link below, historic research notes can also be found on Angles website http://www.angletechnology.com/
http://miranda.hemscott.com/ir/agl/pdf/05EdisonResearch25jan06.pdf
http://miranda.hemscott.com/ir/agl/pdf/05EdisonResearch25jan06.pdf
thorhildur - 02 Feb 2006 22:04 - 4 of 195
.
Tonker
- 03 Feb 2006 09:47
- 5 of 195
I agree with you mate... shares look attractive...
Tole - 04 Feb 2006 14:51 - 6 of 195
Likewise so that three of us :)
Copora (CP.) - (Angle have 10% of this company) looks ready for a move - new broker note due to be published over the next few days on that one I understand. Looks ready for an upwards move there.
Provexis (PXS) - plenty of interest and a nice upwards run - now looking to consolidate over the coming weeks before continuing its next run imo
Copora (CP.) - (Angle have 10% of this company) looks ready for a move - new broker note due to be published over the next few days on that one I understand. Looks ready for an upwards move there.
Provexis (PXS) - plenty of interest and a nice upwards run - now looking to consolidate over the coming weeks before continuing its next run imo
Tonker
- 05 Feb 2006 19:48
- 7 of 195
Am going to keep a good eye on these shares... Wait for the change, will be looking for two rises in a row or a large swing... Also keep eye on trades, company has had a positive interim results, read this [copied]
Financial Highlights
The value of investments (1) on the balance sheet increased by 83% to
5.2 million (2004: 2.9 million).
The flotation of Provexis in June 2005 delivered a gain in valuation
of 2.0 million at the placing price over the cost of investment. The
Provexis share price at close of business on 23 January 2006 values
ANGLE's investment at 6.3 million, a further gain in valuation of
3.2 million since the period end.
Operating costs to establish, develop and create value in Progeny(R)
companies were increased by 107% to 1.8 million (2004: 0.8 million).
This included expenditure on controlled investments (2) of 0.8
million (2004: nil).
Turnover for the half year increased 16% to 2.0 million (2004: 1.7
million).
Loss before tax reduced by 49% to 0.8 million (2004: 1.6 million).
Loss per share reduced by 51% to 4.7p (2004: 9.8p).
Consulting and Management entered the second half with a strong order
book of 8.7 million (2004: 2.8 million) as a result of major new
contracts.
Operational Highlights
Aberro Founded company with experienced management team. Developed
and launched automated software testing product. Revenues expected in
Q1 2006.
Acolyte Biomedica BacLite(R) Rapid MRSA product launched in May 2005
followed by the improved BacLite(R) flex product, launched in
January 2006.
Geomerics Prototype developed demonstrating dramatic speed and
capability improvements for computer games graphics. Building
relationships with major games industry players. High level
management team appointed.
Novocellus Successful development work lead to multi-site
clinical trials being launched in November 2005. Progressed
discussions with major medical diagnostics companies regarding trade
partnership.
Provexis Completed reverse acquisition of Nutrinnovator, flotation on
the Alternative Investment Market, negotiation of distribution
agreements, preparation of Sirco product with launch into the retail
stores of Sainsbury's and Waitrose in January 2006.
Synature Prototype customer classification technology delivered good
first stage results, moving the technology towards full scale
commercial software. Senior management appointed.
Negotiations in progress with major technology corporates, research
establishments and universities for commercialisation of their
intellectual property and several additional Progeny(R) companies
under development.
Financial Highlights
The value of investments (1) on the balance sheet increased by 83% to
5.2 million (2004: 2.9 million).
The flotation of Provexis in June 2005 delivered a gain in valuation
of 2.0 million at the placing price over the cost of investment. The
Provexis share price at close of business on 23 January 2006 values
ANGLE's investment at 6.3 million, a further gain in valuation of
3.2 million since the period end.
Operating costs to establish, develop and create value in Progeny(R)
companies were increased by 107% to 1.8 million (2004: 0.8 million).
This included expenditure on controlled investments (2) of 0.8
million (2004: nil).
Turnover for the half year increased 16% to 2.0 million (2004: 1.7
million).
Loss before tax reduced by 49% to 0.8 million (2004: 1.6 million).
Loss per share reduced by 51% to 4.7p (2004: 9.8p).
Consulting and Management entered the second half with a strong order
book of 8.7 million (2004: 2.8 million) as a result of major new
contracts.
Operational Highlights
Aberro Founded company with experienced management team. Developed
and launched automated software testing product. Revenues expected in
Q1 2006.
Acolyte Biomedica BacLite(R) Rapid MRSA product launched in May 2005
followed by the improved BacLite(R) flex product, launched in
January 2006.
Geomerics Prototype developed demonstrating dramatic speed and
capability improvements for computer games graphics. Building
relationships with major games industry players. High level
management team appointed.
Novocellus Successful development work lead to multi-site
clinical trials being launched in November 2005. Progressed
discussions with major medical diagnostics companies regarding trade
partnership.
Provexis Completed reverse acquisition of Nutrinnovator, flotation on
the Alternative Investment Market, negotiation of distribution
agreements, preparation of Sirco product with launch into the retail
stores of Sainsbury's and Waitrose in January 2006.
Synature Prototype customer classification technology delivered good
first stage results, moving the technology towards full scale
commercial software. Senior management appointed.
Negotiations in progress with major technology corporates, research
establishments and universities for commercialisation of their
intellectual property and several additional Progeny(R) companies
under development.
Tole - 11 Feb 2006 16:29 - 8 of 195
Bit of info off the cs note on potential of the progency companies...note the market size and angle holding figures....
Table 1: Progeny Venture Company Portfolio
Company, Market, Market size, ANGLE holding, Status
Novocellus Human fertility treatment $1bn 63% [1]
- Clinical trials to complete in Q2 2006
- Engaging with commercial partners
Acolyte Bacteria identification $1.3bn 11%
- MRSA diagnostic product launched
- Sales to UK hospitals
NeuroTargets Neuropathic pain treatment $7bn 25%
- Co-development arrangements with several large pharmaceutical companies
Provexis Foods with proven health benefits Rapidly growing 25%
- AIM listed
- Drink launched Jan 06
- Multiple currently 8.5x
Aberro Software testing $1bn+ 57%
- Product launched in Jan 06
- Strong interest
Synature Effective market segmentation of internet users $700m 55% [1]
- Top industry hire secured as CEO
- Product in development
Geomerics Accelerated computer graphics $700m 60% [1]
- Game industry deal expected 2006
- Top game industry hire secured as CEO
Exago Data discovery, summarisation and expertise location $1bn+ 10% of Corpora
- Trade sale for shares to Corpora plc in 2004
- Multiple currently 3x
Table 1: Progeny Venture Company Portfolio
Company, Market, Market size, ANGLE holding, Status
Novocellus Human fertility treatment $1bn 63% [1]
- Clinical trials to complete in Q2 2006
- Engaging with commercial partners
Acolyte Bacteria identification $1.3bn 11%
- MRSA diagnostic product launched
- Sales to UK hospitals
NeuroTargets Neuropathic pain treatment $7bn 25%
- Co-development arrangements with several large pharmaceutical companies
Provexis Foods with proven health benefits Rapidly growing 25%
- AIM listed
- Drink launched Jan 06
- Multiple currently 8.5x
Aberro Software testing $1bn+ 57%
- Product launched in Jan 06
- Strong interest
Synature Effective market segmentation of internet users $700m 55% [1]
- Top industry hire secured as CEO
- Product in development
Geomerics Accelerated computer graphics $700m 60% [1]
- Game industry deal expected 2006
- Top game industry hire secured as CEO
Exago Data discovery, summarisation and expertise location $1bn+ 10% of Corpora
- Trade sale for shares to Corpora plc in 2004
- Multiple currently 3x
Tonker
- 14 Feb 2006 10:54
- 9 of 195
These shares are still flat am getting ready to jump in there..
Tonker
- 18 Feb 2006 16:02
- 10 of 195
still flat... would be nice to see some upward movement... hink they have hit rock botttom...
Technotamed - 18 Feb 2006 19:01 - 11 of 195
This will be the 5th time these shares have gone flat, the previous times it has kept dropping. I will watch and let the market decide which way it goes this time.
Tole - 21 Feb 2006 20:46 - 12 of 195
Well a small tick down - still feel this is the bottom - 50% odd retrace from high.
A bit of old news - but nice to see some coverage of the upcoming games devolpment conference next month where Geomeric (angle have 57%) will be unveiling there new technology....which inevitably should lead to a new games company take up :)
Geomerics and FreestyleGames hire Lincoln Beasley
Ellie Gibson 12:16 08/02/2006
PR firm adds two new clients to roster
Geomerics, which is based in Cambridge, was founded last year and recently hired ex-Kuju director Julian Davis as CTO. The company is set to unveil a new technology based on Geometric Algebra at the Games Development Conference in March. Warwickshire-based FreestyleGames, which was founded by David Osbourn and Jamie Jackson, will announce its first title shortly.
Lincoln Beasley already manages PR for a wide range of companies including Blitz Games, Frontier Developments, Kuju Entertainment and Relentless Software.
MD Alison Beasley commented: "Im extremely pleased to be working for Freestyle and Geomerics and delighted to add them to my small but highly creative stable of talented and savvy game developers."
"Each studio has its own philosophy, strategy, technology and personalities. PR is directly related to sales and, now more than ever, developers need to raise their profiles and shout about what they do.
Geomerics' Julian Davis commented: "Having worked with Lincoln Beasley at Kuju, Im extremely pleased that we can continue to work together now that Ive joined Geomerics. Her industry experience and enthusiasm are invaluable.
FreestyleGames commercial director Chris Lee added: Weve known Alison for a while and have always been impressed with the work that Lincoln Beasley has done for other developers. She has great awareness and knowledge of the industry, understands the requirements of independent developers and shares our passion for what we do.
A bit of old news - but nice to see some coverage of the upcoming games devolpment conference next month where Geomeric (angle have 57%) will be unveiling there new technology....which inevitably should lead to a new games company take up :)
Geomerics and FreestyleGames hire Lincoln Beasley
Ellie Gibson 12:16 08/02/2006
PR firm adds two new clients to roster
Geomerics, which is based in Cambridge, was founded last year and recently hired ex-Kuju director Julian Davis as CTO. The company is set to unveil a new technology based on Geometric Algebra at the Games Development Conference in March. Warwickshire-based FreestyleGames, which was founded by David Osbourn and Jamie Jackson, will announce its first title shortly.
Lincoln Beasley already manages PR for a wide range of companies including Blitz Games, Frontier Developments, Kuju Entertainment and Relentless Software.
MD Alison Beasley commented: "Im extremely pleased to be working for Freestyle and Geomerics and delighted to add them to my small but highly creative stable of talented and savvy game developers."
"Each studio has its own philosophy, strategy, technology and personalities. PR is directly related to sales and, now more than ever, developers need to raise their profiles and shout about what they do.
Geomerics' Julian Davis commented: "Having worked with Lincoln Beasley at Kuju, Im extremely pleased that we can continue to work together now that Ive joined Geomerics. Her industry experience and enthusiasm are invaluable.
FreestyleGames commercial director Chris Lee added: Weve known Alison for a while and have always been impressed with the work that Lincoln Beasley has done for other developers. She has great awareness and knowledge of the industry, understands the requirements of independent developers and shares our passion for what we do.
Tonker
- 02 Mar 2006 08:36
- 13 of 195
These shares are looking steady at the mo. not sure if i should buy now... i need a crystal ball
hobbst - 03 Mar 2006 15:02 - 14 of 195
Been watching these shares since this thread appeared.
They are now at an all time low but I am buggered if I can work out why. Have done all the research and Angle appear to have a cracking pipeline of business' and they also appear to have turned around the consultancy arm.
Could not resist such an undervalued stock (imho) and have taken a maiden stake.
They are now at an all time low but I am buggered if I can work out why. Have done all the research and Angle appear to have a cracking pipeline of business' and they also appear to have turned around the consultancy arm.
Could not resist such an undervalued stock (imho) and have taken a maiden stake.
Technotamed - 03 Mar 2006 16:14 - 15 of 195
These have been on my watch list since Nov, having sold some eme to buy these today.
Tonker
- 06 Mar 2006 07:58
- 16 of 195
How will the placing announced today affect sp
Tonker
- 06 Mar 2006 08:18
- 17 of 195
Just made a buy at 88p 1300shares.... made a market move because bread price move up 1p each after.... could this be the start of a rally....
Tonker
- 06 Mar 2006 10:40
- 18 of 195
Large buy of 25,000 at 8.37.. only just came through. they paid a high price 91p.
Tole - 07 Mar 2006 17:33 - 19 of 195
Angle had a nice write up in the Mail this weekend - focusing on Novocellus.
"The prsospect of its Novocellus offshoot, which aims to improve the success rate of fertility treatment looks enticing and have the potential to reverse teh decline in Angles shares which have drifted to 83.5p."
A few points mentioned on Novocellus -
1. Huge demand for IVF treatments
2. Recent first results showed 34% improvement in patients, larger studies currently underway.
3. If these confirm the findings - submited EU approval - on the market 2007
4. Unclear as yet what Novocellus would charge for its treatment, however 200-250 looks feasible. Equating global market worth 140m a year. If won 10% of this - revenues would be 14m, (assuming 25% margin) pretax of 3.5m. Valuing this at 16x earnings would price Novocellus at 40m with Angles 63% at 27m.
5. This 27m is nearly double Angles current stock market value of 14m
Also goes on to point out the other progency companies - highlighting their potential....
Sums up with what we all know -
"One big winner could change the picture. Its backers are now crossing their fingers that Novocellus will be the one."
Have to say I still personally fancy Geomerics myself - But obviuosuly will be happy with Novocellus being the jewel in the crown here :)
"The prsospect of its Novocellus offshoot, which aims to improve the success rate of fertility treatment looks enticing and have the potential to reverse teh decline in Angles shares which have drifted to 83.5p."
A few points mentioned on Novocellus -
1. Huge demand for IVF treatments
2. Recent first results showed 34% improvement in patients, larger studies currently underway.
3. If these confirm the findings - submited EU approval - on the market 2007
4. Unclear as yet what Novocellus would charge for its treatment, however 200-250 looks feasible. Equating global market worth 140m a year. If won 10% of this - revenues would be 14m, (assuming 25% margin) pretax of 3.5m. Valuing this at 16x earnings would price Novocellus at 40m with Angles 63% at 27m.
5. This 27m is nearly double Angles current stock market value of 14m
Also goes on to point out the other progency companies - highlighting their potential....
Sums up with what we all know -
"One big winner could change the picture. Its backers are now crossing their fingers that Novocellus will be the one."
Have to say I still personally fancy Geomerics myself - But obviuosuly will be happy with Novocellus being the jewel in the crown here :)
Tole - 10 Mar 2006 10:10 - 20 of 195
Investors Chronicle
10 March 2006
Share placing to widen angle appeal
Angle, which commercialises technology, has raised 8.1m in a placing at 79p a share. On completion, the new shares will represent 38 per cent of the total shares in issue. The proceeds will be used to develop the existing portfolio of companies and to establish new companies.
Angle's shares have performed poorly, but the placing should help to secure the future pipeline of developments. At 83p, the shares are good value.
10 March 2006
Share placing to widen angle appeal
Angle, which commercialises technology, has raised 8.1m in a placing at 79p a share. On completion, the new shares will represent 38 per cent of the total shares in issue. The proceeds will be used to develop the existing portfolio of companies and to establish new companies.
Angle's shares have performed poorly, but the placing should help to secure the future pipeline of developments. At 83p, the shares are good value.
Tole - 15 Mar 2006 21:56 - 21 of 195
IVF test promises new life for Angle
Brian O'Connor, Daily Mail
6 March 2006
SIGNS of life are appearing at Angle, the backer of young technology companies which has been an underperformer since first tipped here 13 months ago at 126p.
The prospects of its Novocellus offshoot, which aims to improve the success rate of fertility treatment, look enticing, and have the potential to reverse the decline in Angle's shares, which have drifted to 83p.
This spotlights the potential of the Angle portfolio,which also includes Geomerics, whose technology could enhance computer games graphics.
Novocellus is working on in-vitro fertilisation (IVF) the technique on which many childless couples spend thousands of pounds. There is huge demand for IVF treatment, but success rates can be low.
Based on the work of a professor at the University of York, Novocellus has developed a test which, on first indications, may improve success rates by up to one-third.
Basically, IVF fertilises several eggs outside the womb and selects one or two to reinsert. Selecting the strongest is crucial but tricky. Novocellus analyses the amino acids around the embryo, which signal how healthy it is.
The results of a first test on 53 women gave a 34% improvement. A bigger study of 400 is under way in the Midlands.
It is early days, but if this confirms the findings of the first study, the test can be submitted for EU approval. If all goes well, it could be on the market in 2007.
This is where the sums get exciting. IVF is expensive - a successful birth can take up to five attempts, costing as much as 10,000. Cutting this to four would save 2,000.
It remains to be seen what Novocellus could charge for its test, but 200 to 250 looks feasible. At 250, the potential global market would be worth 140m a year. If it won 10% of this, its revenues would be 14m, with pretax profits, assuming a 25% margin, of 3.5m. Valuing this at 16 times earnings would price Novocellus at 40m and Angle's 63% at 27m.
This is nearly double Angle's present stock market value of 14m - though the need to finance its development programme means that a further share issue is on the cards.
Many things could go wrong. The current study may prove disappointing. Bringing such diagnostic tests to market can be slow. Competition could arrive - though at present Novocellus seems to be ahead.
Angle boss Andrew Newland has several other projects in his pipeline. Neurotargets is seeking relief for chronic nerve pain. Acolyte Biomedica aims to cut diagnosis times to speed up the effectiveness of antibiotics.
Provexis has its Sirco healthy fruit juice on sale in supermarkets. Its shares have been a slow burner, but Angle's 25% is worth 6.5m.
Angle's consultants earn a regular flow of fee income, which keep it funded while it nurtures its portfolio of hopefuls. One big winner could change the picture. Its backers are now crossing their fingers that Novocellus will be the one.
Brian O'Connor, Daily Mail
6 March 2006
SIGNS of life are appearing at Angle, the backer of young technology companies which has been an underperformer since first tipped here 13 months ago at 126p.
The prospects of its Novocellus offshoot, which aims to improve the success rate of fertility treatment, look enticing, and have the potential to reverse the decline in Angle's shares, which have drifted to 83p.
This spotlights the potential of the Angle portfolio,which also includes Geomerics, whose technology could enhance computer games graphics.
Novocellus is working on in-vitro fertilisation (IVF) the technique on which many childless couples spend thousands of pounds. There is huge demand for IVF treatment, but success rates can be low.
Based on the work of a professor at the University of York, Novocellus has developed a test which, on first indications, may improve success rates by up to one-third.
Basically, IVF fertilises several eggs outside the womb and selects one or two to reinsert. Selecting the strongest is crucial but tricky. Novocellus analyses the amino acids around the embryo, which signal how healthy it is.
The results of a first test on 53 women gave a 34% improvement. A bigger study of 400 is under way in the Midlands.
It is early days, but if this confirms the findings of the first study, the test can be submitted for EU approval. If all goes well, it could be on the market in 2007.
This is where the sums get exciting. IVF is expensive - a successful birth can take up to five attempts, costing as much as 10,000. Cutting this to four would save 2,000.
It remains to be seen what Novocellus could charge for its test, but 200 to 250 looks feasible. At 250, the potential global market would be worth 140m a year. If it won 10% of this, its revenues would be 14m, with pretax profits, assuming a 25% margin, of 3.5m. Valuing this at 16 times earnings would price Novocellus at 40m and Angle's 63% at 27m.
This is nearly double Angle's present stock market value of 14m - though the need to finance its development programme means that a further share issue is on the cards.
Many things could go wrong. The current study may prove disappointing. Bringing such diagnostic tests to market can be slow. Competition could arrive - though at present Novocellus seems to be ahead.
Angle boss Andrew Newland has several other projects in his pipeline. Neurotargets is seeking relief for chronic nerve pain. Acolyte Biomedica aims to cut diagnosis times to speed up the effectiveness of antibiotics.
Provexis has its Sirco healthy fruit juice on sale in supermarkets. Its shares have been a slow burner, but Angle's 25% is worth 6.5m.
Angle's consultants earn a regular flow of fee income, which keep it funded while it nurtures its portfolio of hopefuls. One big winner could change the picture. Its backers are now crossing their fingers that Novocellus will be the one.
Tonker
- 15 Mar 2006 22:01
- 22 of 195
Tanks for the info Tole.. I am a holder and can not wait for the price to rise... LCP is another good investment company... I have started a thread
Tonker
- 17 Mar 2006 12:54
- 23 of 195
Quote from Shares mag pg 11
Angle reaps Fruit of Provexis's labours
Specialist intellectual property investment firm AGL could be in for a bumper pay day thanks to the success of Fruitflow, a compount which helps cut the threat of heart attacks, blood clots and strokes....
Angle reaps Fruit of Provexis's labours
Specialist intellectual property investment firm AGL could be in for a bumper pay day thanks to the success of Fruitflow, a compount which helps cut the threat of heart attacks, blood clots and strokes....
thesaurus - 17 Mar 2006 13:51 - 24 of 195
No change in the share price though....
Tonker
- 17 Mar 2006 14:55
- 25 of 195
I know... what will get these buggers to move up north... fustrating
Tole - 22 Mar 2006 17:10 - 26 of 195
An updated research note out earlier this month. Free to view the full article.
http://www.brokerlink.co.uk/angle.pdf
Profile -
The share placing announced by ANGLE to raise up to 8.1m will enable it to further develop its Ventures business, which has enjoyed considerable success to date.
This can be demonstrated by the flotation of one of its Venture companies, Provexis, last June. At the time of flotation, ANGLE's stake in the company was worth 3.5m, giving the group a profit of 2.0m and by the end of January, due to the rise in the Provexis share price, this stake was worth 6.4m.
The group's Consulting and Management business entered the second half with a strong order book, meaning that the outlook for the company is very encouraging and the shares could recover strongly over the next few months.
http://www.brokerlink.co.uk/angle.pdf
Profile -
The share placing announced by ANGLE to raise up to 8.1m will enable it to further develop its Ventures business, which has enjoyed considerable success to date.
This can be demonstrated by the flotation of one of its Venture companies, Provexis, last June. At the time of flotation, ANGLE's stake in the company was worth 3.5m, giving the group a profit of 2.0m and by the end of January, due to the rise in the Provexis share price, this stake was worth 6.4m.
The group's Consulting and Management business entered the second half with a strong order book, meaning that the outlook for the company is very encouraging and the shares could recover strongly over the next few months.
Tole - 28 Mar 2006 18:45 - 27 of 195
Another new research note out this month (21st March 06) from Fyshe Horton - available through the investors section on Angles website. Ive posted the link below.
http://miranda.hemscott.com/ir/agl/pdf/FysheHortonFinneyANGLEResearchNotemar06.pdf
A nice summary here -
"Our calculations point to aconsiderable uplift in price and we suspect that the recent fundraising could be the catalyst to trigger a change in sentiment and appreciation in price. What is clear is that the potential of the six un-exited progency companies is not fully reflected. Indeed our calculations suggest that at the current price, the implied value of these investments is only 1.5 million. A fair assessment of the underlying business reveals that this is inadeqaute. If ANGLE can further develop its C&M business whilst continuing to demonstrate the ability to realise value from its Progency companies, the potential exists for a significant re-rating of the shares. BUY"
http://miranda.hemscott.com/ir/agl/pdf/FysheHortonFinneyANGLEResearchNotemar06.pdf
A nice summary here -
"Our calculations point to aconsiderable uplift in price and we suspect that the recent fundraising could be the catalyst to trigger a change in sentiment and appreciation in price. What is clear is that the potential of the six un-exited progency companies is not fully reflected. Indeed our calculations suggest that at the current price, the implied value of these investments is only 1.5 million. A fair assessment of the underlying business reveals that this is inadeqaute. If ANGLE can further develop its C&M business whilst continuing to demonstrate the ability to realise value from its Progency companies, the potential exists for a significant re-rating of the shares. BUY"
Tole - 05 Apr 2006 21:04 - 28 of 195
And more importantly announced today - good to see Fidelity here and nice of them to pick up 10% :)
FMR Corp and Fidelity International Limited (FIL) and their direct and indirect
subsidiaries
Number of shares / amount of stock acquired: 2,658,227
Percentage of issued class 9.80%
FMR Corp and Fidelity International Limited (FIL) and their direct and indirect
subsidiaries
Number of shares / amount of stock acquired: 2,658,227
Percentage of issued class 9.80%
Tole - 29 Apr 2006 21:12 - 29 of 195
http://www.e4engineering.com/Articles/294235/Taking+a+new+angle.htm
Taking a new angle against power tool vibration
Published: 20 April 2006 02:00 PM
Source: The Engineer
Angle, a venture management business specialising in the commercialisation of technology, has signalled its intention to enter the power tool industry with the launch of a new company called Innomatica.
The new business has secured intellectual property which it claimed could revolutionise the global market for percussive power tools by reducing operator exposure to vibration the principal cause of medical conditions such as vibration white finger (VWF).
Last year new legislation known as the Physical Agents (Vibration) Directive was implemented throughout Europe, and was approved by the UK Parliament as The Control of Vibration at Work Regulations.
This will enforce specific limits on employee exposure to vibration in the workplace.
According to Innomatica, the only current method to reduce the vibrations generated by percussive power tools such as road drills is through increasing the mass of the tool, which in turn raises further regulatory and practical issues. The result is that employees either spend a limited time using the tool or use equipment specifically underpowered to comply with the regulations.
The company believes the solution to this problem is variable mass technology, developed over 10 years at Cambridge University and power tool companies. This reduces vibration to a level that enables an operator to use a power tool up to four times as long as existing products, it is claimed.
Angle's chief executive Andrew Newland said: 'The power tools and construction industries are worth $1.2bn (680m) a year and they have long awaited a solution to injuries caused by vibration power tools.'
In 2001, over 35 per cent of employer's liability in insurance claims were for Hand Arm Vibration Syndrome (HAVS), a condition caused by exposure to hand-transmitted vibration. The Health and Safety Executive estimates there are approximately 300,000 sufferers of VWF, the most common form of HAVS in the UK, with two million people regularly exposed to high levels of vibration.
Taking a new angle against power tool vibration
Published: 20 April 2006 02:00 PM
Source: The Engineer
Angle, a venture management business specialising in the commercialisation of technology, has signalled its intention to enter the power tool industry with the launch of a new company called Innomatica.
The new business has secured intellectual property which it claimed could revolutionise the global market for percussive power tools by reducing operator exposure to vibration the principal cause of medical conditions such as vibration white finger (VWF).
Last year new legislation known as the Physical Agents (Vibration) Directive was implemented throughout Europe, and was approved by the UK Parliament as The Control of Vibration at Work Regulations.
This will enforce specific limits on employee exposure to vibration in the workplace.
According to Innomatica, the only current method to reduce the vibrations generated by percussive power tools such as road drills is through increasing the mass of the tool, which in turn raises further regulatory and practical issues. The result is that employees either spend a limited time using the tool or use equipment specifically underpowered to comply with the regulations.
The company believes the solution to this problem is variable mass technology, developed over 10 years at Cambridge University and power tool companies. This reduces vibration to a level that enables an operator to use a power tool up to four times as long as existing products, it is claimed.
Angle's chief executive Andrew Newland said: 'The power tools and construction industries are worth $1.2bn (680m) a year and they have long awaited a solution to injuries caused by vibration power tools.'
In 2001, over 35 per cent of employer's liability in insurance claims were for Hand Arm Vibration Syndrome (HAVS), a condition caused by exposure to hand-transmitted vibration. The Health and Safety Executive estimates there are approximately 300,000 sufferers of VWF, the most common form of HAVS in the UK, with two million people regularly exposed to high levels of vibration.
Tole - 19 May 2006 17:46 - 30 of 195
oops wrong thread
Tole - 21 Jun 2006 18:06 - 31 of 195
Tipped as a buy in HL's 'In the City' publication this month - highlight the potential in their progency companies.....
hangon - 01 May 2007 10:25 - 32 of 195
Well, here we are nearly one year later...and there is little interest from Punters - the Co website is a bit flakey and all these technologies are "could do's" - OR - "might be's" - there being little definate progression....something that many IP co's will suffer and the more diverse the IP the greater the risks that few will understand exactly what is at stake.
Meanwhile, the money drains and fear of a dilution/cash calls etc. This co did manage to sell one business to 3M - quite a good deal, but one wonders who got the better deal as it's made little difference to the sp. Further cash should come in 2008 but meanwhile folk think they can leave this one until someone explains it. . . . . Anyone?
I have some money in BTG[BGC] which is now almost completely medical IP - - - because of the risks associated with physical (and software) companies:- it's just too easy for execs to fall in love with their efforts until suddenly they find someone else has beaten them to Market - at which point they might as well stop.
Years of cash and effort might be protected by a Patent, but if the Market is satisfied by another technology (often better!) then having a piece of paper - has no value......I wonder of Angle Execs are really up to the job of promoting their various businesses - I can't recall One (until I read their website) and even now they are easily forgotten.
The sp is slipping and I suspect it will continue to fall until the cash is nearer to the Mkt Cap.....at present there is some way to go.
Meanwhile, the money drains and fear of a dilution/cash calls etc. This co did manage to sell one business to 3M - quite a good deal, but one wonders who got the better deal as it's made little difference to the sp. Further cash should come in 2008 but meanwhile folk think they can leave this one until someone explains it. . . . . Anyone?
I have some money in BTG[BGC] which is now almost completely medical IP - - - because of the risks associated with physical (and software) companies:- it's just too easy for execs to fall in love with their efforts until suddenly they find someone else has beaten them to Market - at which point they might as well stop.
Years of cash and effort might be protected by a Patent, but if the Market is satisfied by another technology (often better!) then having a piece of paper - has no value......I wonder of Angle Execs are really up to the job of promoting their various businesses - I can't recall One (until I read their website) and even now they are easily forgotten.
The sp is slipping and I suspect it will continue to fall until the cash is nearer to the Mkt Cap.....at present there is some way to go.
coeliac1 - 01 May 2007 12:34 - 33 of 195
Looks like the Daily Mail has suckered a few people into this dog.
hangon - 06 Feb 2008 17:01 - 34 of 195
SP abt 35pence - wow! [EDIT: 4April-08 - 26p !)
Looks like things are sliding....due mainly to nothing positive to excite the punters - OK that's not what a company should be doing - but after this length of time you'd think there would be something to say.....rather than the usual dry RNS.
. . . . . . . . . . . . . . . . . . . . . . . . . . Does anyone know their cash-position ?
(yes, I know the 3M-cash is yet to flow...that Won't help this year, the way I read it. Furthermore does anyone know if this is in Dollars ( and therefore sliding, itself!). Arrgh. I don't hold yet....don't like "promises" and don't like situations where they set-up their own businesses ( which is in-part the way I see Angle)
Investing in Start-ups is OK as these are run by people with "passion" and presumably some expertise in their target area.
What do others think of this Co????
Looks like things are sliding....due mainly to nothing positive to excite the punters - OK that's not what a company should be doing - but after this length of time you'd think there would be something to say.....rather than the usual dry RNS.
. . . . . . . . . . . . . . . . . . . . . . . . . . Does anyone know their cash-position ?
(yes, I know the 3M-cash is yet to flow...that Won't help this year, the way I read it. Furthermore does anyone know if this is in Dollars ( and therefore sliding, itself!). Arrgh. I don't hold yet....don't like "promises" and don't like situations where they set-up their own businesses ( which is in-part the way I see Angle)
Investing in Start-ups is OK as these are run by people with "passion" and presumably some expertise in their target area.
What do others think of this Co????
hangon - 07 Apr 2008 23:01 - 35 of 195
(( SP rises to 40p ))
Gulp! - a 60p bid is suggested ( DYOR _ read RNS).
Odd this, as the Market let this fall to 26p (4 April"08, - see my earlier Post)
AND yet this thread suggested 1.65 (probably Jan06) - so I expect the Board will reject anything that's not "close" to this figure....
Gulp! - a 60p bid is suggested ( DYOR _ read RNS).
Odd this, as the Market let this fall to 26p (4 April"08, - see my earlier Post)
AND yet this thread suggested 1.65 (probably Jan06) - so I expect the Board will reject anything that's not "close" to this figure....
Confidant - 09 Apr 2008 12:58 - 36 of 195
Do i not understand this share price
Indicative bid -- all share is 60p -- stock trading at 41p. Sure could fall through but please
hangon you suggest board will reject but times change. Plus all share offer -- perhaps from another small co mean they can participate in upside if they really believe. i.e. hold on to their shares
Still looks like some doubters out there. But sorry i've not been able to resist here
Indicative bid -- all share is 60p -- stock trading at 41p. Sure could fall through but please
hangon you suggest board will reject but times change. Plus all share offer -- perhaps from another small co mean they can participate in upside if they really believe. i.e. hold on to their shares
Still looks like some doubters out there. But sorry i've not been able to resist here
hangon - 13 Nov 2008 14:42 - 37 of 195
Anyone still here, bought at 1.65 ? - well, it's 9p right now....time to top-up (or get out)...this has been a serial disapointer - clearly it was never likley to prosper in the medium-term...after an investment these small-caps take for Ages to create a Return ( Looking at "value" is wrong - since the Market will tend to fall until there is a Dividend prospect...only that shows the business is sound.
Anyone been to their AGM, or are on the Isle of Skye at 8.30am on Sunday...grr.
Anyone been to their AGM, or are on the Isle of Skye at 8.30am on Sunday...grr.
mitzy - 04 Jan 2010 10:33 - 38 of 195
Top performer this start of the year
hlyeo98 - 04 Jan 2010 10:46 - 39 of 195
This is still too risky to take a venture at 19p imo.
mitzy - 04 Jan 2010 10:55 - 40 of 195
Could be risky a poster called tara is calling 100 long trm I doubt it very much.
hlyeo98 - 04 Jan 2010 14:59 - 41 of 195
mitzy - 05 Jan 2010 15:20 - 42 of 195
What a load of rubbish.
mitzy - 06 Jan 2010 11:26 - 43 of 195
This is manipulated by the mm's.
Lord Gnome
- 06 Jan 2010 19:54
- 44 of 195
Excuse my scepticism, but having had a cursory glance at this one I just can't see what all the fuss is about. It has attracted some knowledgeable posters over the road at advfn and that is the only reason I am interested.
Dil
- 06 Jan 2010 21:14
- 45 of 195
Like who ?
mitzy - 06 Jan 2010 21:26 - 46 of 195
I know barnetpeter likes this one and he tipped Asos at 3p and now 4 years on its..500p..also Cockney Rebel has bought.
I reckon they are worth 50p a share.
I reckon they are worth 50p a share.
HARRYCAT
- 06 Jan 2010 21:33
- 47 of 195
So, for the unenlightened, what is the fuss all about, please?
mitzy - 07 Jan 2010 08:45 - 48 of 195
Dil
- 07 Jan 2010 09:28
- 49 of 195
Put a 5 year chart up mitzy :-)
Looks like a classic ramp to me but good luck.
Looks like a classic ramp to me but good luck.
moneyplus
- 07 Jan 2010 12:29
- 50 of 195
sorry I missed this one but too hot for me now--will watch with interest.
mitzy - 07 Jan 2010 12:40 - 51 of 195
Thanks Dil now up 20% should get to 30p Friday.
ravey davy gravy
- 07 Jan 2010 13:02
- 52 of 195
It is a classic ramp from some of advfn's finest pump and dumpers !
When a thread headline on a 15p stock says 100 a share you know
it's a pump and dump.
Tara is notorious for doing this
When a thread headline on a 15p stock says 100 a share you know
it's a pump and dump.
Tara is notorious for doing this
hlyeo98 - 07 Jan 2010 13:13 - 53 of 195
I would dump now before somebody does if I was a holder.
It's a case of who's dumping quicker here.
It's a case of who's dumping quicker here.
mitzy - 07 Jan 2010 16:04 - 54 of 195
When she dumps.
mitzy - 08 Jan 2010 09:00 - 55 of 195
Still rising..
hlyeo98 - 08 Jan 2010 09:59 - 56 of 195
And the steeper it falls. That's pump and dump.
HARRYCAT
- 08 Jan 2010 10:20
- 57 of 195
Nevertheless, really good money to be made for those brave enough!
mitzy - 08 Jan 2010 11:54 - 58 of 195
Yep good money at the end of the day.
Dil
- 08 Jan 2010 11:57
- 59 of 195
You cashed in yet mitzy or you waiting for the 100 ?
:-)
:-)
mitzy - 08 Jan 2010 13:18 - 60 of 195
still hold will hold for 50p.
mitzy - 11 Jan 2010 11:11 - 61 of 195
Holding up well today which is great because this is ridiculously cheap.
mitzy - 12 Jan 2010 09:00 - 62 of 195
mitzy - 13 Jan 2010 14:19 - 63 of 195
Up and away..
moneyplus
- 13 Jan 2010 19:54
- 64 of 195
I'm kicking myself I passed on this one! I put NYO and FTE in my isa today--are you in those Mitzy?
mitzy - 13 Jan 2010 20:17 - 65 of 195
Yep holding from 20p moneyplus could rocket to a couple of quid or go bust...will see.
mitzy - 14 Jan 2010 15:26 - 66 of 195
Dear me its down 10%..
ravey davy gravy
- 14 Jan 2010 15:54
- 67 of 195
Are the wheels coming away now ?
Maybe Tara will have to start a Angle 500 a share thread to get it back up :-))
Maybe Tara will have to start a Angle 500 a share thread to get it back up :-))
mitzy - 14 Jan 2010 17:40 - 68 of 195
lol..
mitzy - 20 Jan 2010 08:42 - 69 of 195
Where is Tara today..lol.
mitzy - 20 Jan 2010 14:21 - 70 of 195
Guys this is going all the way.
mitzy - 20 Jan 2010 17:57 - 71 of 195
Wow this is great up 23% and more.
mitzy - 21 Jan 2010 09:27 - 72 of 195
down 15% lol.
ravey davy gravy
- 22 Jan 2010 10:52
- 73 of 195
Course it's going down, most of the profits were made from a profit on a PXS sale,
now to keep making those kind of profits they need to keep finding a stock that did what Pxs did which was 1p or less upto a 23p high, you need a crystal ball to do that every 6 months and would be lucky to that every six years, a huge pump and dump that has completely fizzled out and now the stock will only attract day traders trying to skim on the bounces intraday.
now to keep making those kind of profits they need to keep finding a stock that did what Pxs did which was 1p or less upto a 23p high, you need a crystal ball to do that every 6 months and would be lucky to that every six years, a huge pump and dump that has completely fizzled out and now the stock will only attract day traders trying to skim on the bounces intraday.
willpe - 17 Feb 2010 12:37 - 74 of 195
Part of an email I received today morning:
...Angle aims to secure a deal for its other major investment, 78%-owned Parsortix, by April 2011. Parsortix has developed the first ever non-invasive testing platform for the unborn baby. Pregnant women have a very small number of their baby's cells circulating in their blood; at most one foetal cell for 500 million maternal cells. Parsortix has developed a separation device, which can isolate intact foetal cells in maternal blood (as opposed to merely DNA fragments) when only 1.5ml of maternal blood is flowed through the device. The current method of testing carries substantial risk for both mother and baby, and is limited to high risk category patients where an invasive procedure can be justified.
Parsortix's method would be both cheaper and safer than conventional testing, so the market potential is pretty obvious. In the US market alone there are currently 375,000 such invasive tests undertaken per annum leaving the remaining 2.2 million pregnancies with no advance warning of potential problems. Assuming 11 million births per annum in industrialised countries and a cost of $200 per test, capturing just 3% of this market would generate substantial royalties (at 15%: c.$10 million per annum). News of a commercial partner for this technology on the lines of the Novocellus deal could drive the shares sharply higher in the near future. Buy. http://uk-analyst.com/shop/page-article/action-article.show/id-130003216
...Angle aims to secure a deal for its other major investment, 78%-owned Parsortix, by April 2011. Parsortix has developed the first ever non-invasive testing platform for the unborn baby. Pregnant women have a very small number of their baby's cells circulating in their blood; at most one foetal cell for 500 million maternal cells. Parsortix has developed a separation device, which can isolate intact foetal cells in maternal blood (as opposed to merely DNA fragments) when only 1.5ml of maternal blood is flowed through the device. The current method of testing carries substantial risk for both mother and baby, and is limited to high risk category patients where an invasive procedure can be justified.
Parsortix's method would be both cheaper and safer than conventional testing, so the market potential is pretty obvious. In the US market alone there are currently 375,000 such invasive tests undertaken per annum leaving the remaining 2.2 million pregnancies with no advance warning of potential problems. Assuming 11 million births per annum in industrialised countries and a cost of $200 per test, capturing just 3% of this market would generate substantial royalties (at 15%: c.$10 million per annum). News of a commercial partner for this technology on the lines of the Novocellus deal could drive the shares sharply higher in the near future. Buy. http://uk-analyst.com/shop/page-article/action-article.show/id-130003216
gibby - 28 Sep 2011 12:51 - 75 of 195
those in before today's hike should consider selling and buying back later!!! :-))))
HARRYCAT
- 28 Sep 2011 13:48
- 76 of 195
WH Ireland note:
"ANGLE has announced that its 85% owned US-based portfolio company, Parsortix Inc. has completed a study demonstrating that its cell separation device reproducibly isolates and captures tumour cells in cancer patient blood, and emphasises that the cancer cells can be identified within the device without requiring a complicated cell extraction process. These are highly promising findings, which ANGLE believes give the technology an immediate market application in cancer research enabling sales of the product for research purposes from the second half of 2012.
Following this, the next step is to replicate these results in larger clinical trials to obtain US and European regulatory marketing approvals, which would enable Parsortix Inc. to sell the technology as a cost-effective, non-invasive, reliable screening tool to improve cancer treatment through early detection of cancer and monitoring of cancer patients while receiving treatment and those in remission. ANGLE estimates that the addressable clinical market for a simple circulating tumour cells counting device in the US alone exceeds $4 billion per annum."
"ANGLE has announced that its 85% owned US-based portfolio company, Parsortix Inc. has completed a study demonstrating that its cell separation device reproducibly isolates and captures tumour cells in cancer patient blood, and emphasises that the cancer cells can be identified within the device without requiring a complicated cell extraction process. These are highly promising findings, which ANGLE believes give the technology an immediate market application in cancer research enabling sales of the product for research purposes from the second half of 2012.
Following this, the next step is to replicate these results in larger clinical trials to obtain US and European regulatory marketing approvals, which would enable Parsortix Inc. to sell the technology as a cost-effective, non-invasive, reliable screening tool to improve cancer treatment through early detection of cancer and monitoring of cancer patients while receiving treatment and those in remission. ANGLE estimates that the addressable clinical market for a simple circulating tumour cells counting device in the US alone exceeds $4 billion per annum."
gibby - 28 Sep 2011 16:11 - 77 of 195
one for the future here when sp reverses
machoman - 28 Sep 2011 16:28 - 78 of 195
gibby
re - those in before today's hike should consider selling and buying back later!!! :-))))
The time is not right for taking profits, I would say it has to go much much higher than the 56p at the time of you comment, think about a price close to 100p, though 85p could be a difficult price to go over
re - those in before today's hike should consider selling and buying back later!!! :-))))
The time is not right for taking profits, I would say it has to go much much higher than the 56p at the time of you comment, think about a price close to 100p, though 85p could be a difficult price to go over
machoman - 28 Sep 2011 17:04 - 79 of 195
A lovely intraday UP trend, only falling a bit at 4pm after steady pause, as the profit takers (trades ) were busy cashing in for the day.
expect good comments on the press tomorrow and brokers making new updates
expect good comments on the press tomorrow and brokers making new updates
machoman - 28 Sep 2011 17:10 - 80 of 195
from ...growth company
ANGLE soars on cancer breakthrough
28/09/2011 Robert Tyerman
Shares in intellectual property backer ANGLE (AGL) have doubled on successful cancer cell separation by its US diagnostics company, Parsortix.
Guildford-based ANGLE says Parsortix, of which it owns 85 per cent, has 'validated' that its patented cell separation device can capture cancer cells added to blood.
AIM-quoted ANGLE says this device can be used, on a reproducible basis, to 'isolate and capture very small numbers of cancer cells from whole blood'. The company declares that the device 'appears to capture efficiently all of the cancer cells, avoiding the risk of failing to detect cancer cells in a blood sample' and 'allows the identification of cancer cells within the device, without requiring a complicated cell extraction process'.
ANGLE contends that the Parsortix device has immediate market application for research and says it has started talking to 'several of the world's leading cancer research institutes', with the aim of selling the product for research as early as the second half of next year. The company adds that it has also opened discussions about collaborating with major global diagnostic concerns.
Beyond this lies the possibility of selling a product direct, subject to key regulatory approvals, and targeting the blood test market, estimated to be worth more than 2.5 billion in the USA alone. ANGLE says its target is to seek approval from the US Food and Drug Administration and the European authorities by mid-2013, allowing commercial sales for cancer detection, cancer patient monitoring and post-treatment monitoring.
Andew Newland, founder, chief executive and substantial ANGLE shareholder, says Parsortix's cancer diagnostic 'offers an outstanding commercial opportunity'. Investors agree and have sent the shares, highlighted by Growth Company Investor in July at 27p, up 28.25p today to 56.25p, valuing the company at nearly 20 million.
Hold on for now.
ANGLE soars on cancer breakthrough
ANGLE soars on cancer breakthrough
28/09/2011 Robert Tyerman
Shares in intellectual property backer ANGLE (AGL) have doubled on successful cancer cell separation by its US diagnostics company, Parsortix.
Guildford-based ANGLE says Parsortix, of which it owns 85 per cent, has 'validated' that its patented cell separation device can capture cancer cells added to blood.
AIM-quoted ANGLE says this device can be used, on a reproducible basis, to 'isolate and capture very small numbers of cancer cells from whole blood'. The company declares that the device 'appears to capture efficiently all of the cancer cells, avoiding the risk of failing to detect cancer cells in a blood sample' and 'allows the identification of cancer cells within the device, without requiring a complicated cell extraction process'.
ANGLE contends that the Parsortix device has immediate market application for research and says it has started talking to 'several of the world's leading cancer research institutes', with the aim of selling the product for research as early as the second half of next year. The company adds that it has also opened discussions about collaborating with major global diagnostic concerns.
Beyond this lies the possibility of selling a product direct, subject to key regulatory approvals, and targeting the blood test market, estimated to be worth more than 2.5 billion in the USA alone. ANGLE says its target is to seek approval from the US Food and Drug Administration and the European authorities by mid-2013, allowing commercial sales for cancer detection, cancer patient monitoring and post-treatment monitoring.
Andew Newland, founder, chief executive and substantial ANGLE shareholder, says Parsortix's cancer diagnostic 'offers an outstanding commercial opportunity'. Investors agree and have sent the shares, highlighted by Growth Company Investor in July at 27p, up 28.25p today to 56.25p, valuing the company at nearly 20 million.
Hold on for now.
ANGLE soars on cancer breakthrough
machoman - 28 Sep 2011 17:21 - 81 of 195
Proactive investors
In the meantime, todays big news from Angle (LON:AGL) went somewhat unnoticed, buried under the pile of reported from the oil and gas sector.
However, the company emerged among the most actively discussed stocks on message boards after seeing its share price double on the announcement that its 85 percent owned company Parsortix has validated that its cell separation device can capture cancer cells added to blood.
The group has already entered discussions with what it said were several of the world's leading cancer research institutes and reported strong interest in such a product, which would require regulatory approval for use for research purposes.
Angle is targeting to sell the product for research purposes as early as the second half of 2012.
We see this as not just a major validation of the Parsortix technology, but a significant broadening of Angles commercial opportunity...by this point, we would anticipate Parsortix to have attracted commercial interest from majors, said analysts at Collins Stewart.
The broker currently has a target price of 44 pence for the stock, however, it may want to update it after the companys share price rose from 28 pence to 56 pence this afternoon.
However, Collins Stewart noted in todays report that its valuation only presently ascribes partial value to 1 venture. The broker added that the success of any of the opportunities in its venture portfolio would highlight significant upside optionality in the Groups current share price.
Many investors following Angle agreed, noting that even after the increase, the company still has a market cap of 20 million, which, in their opinion, does not reflect the commercial potential of Parsortix.
http://www.proactiveinvestors.co.uk/companies/news/33689/wednesdays-most-followed-man-group-red-emperor-resources-dominos-pizza-angle-plc-33689.html
In the meantime, todays big news from Angle (LON:AGL) went somewhat unnoticed, buried under the pile of reported from the oil and gas sector.
However, the company emerged among the most actively discussed stocks on message boards after seeing its share price double on the announcement that its 85 percent owned company Parsortix has validated that its cell separation device can capture cancer cells added to blood.
The group has already entered discussions with what it said were several of the world's leading cancer research institutes and reported strong interest in such a product, which would require regulatory approval for use for research purposes.
Angle is targeting to sell the product for research purposes as early as the second half of 2012.
We see this as not just a major validation of the Parsortix technology, but a significant broadening of Angles commercial opportunity...by this point, we would anticipate Parsortix to have attracted commercial interest from majors, said analysts at Collins Stewart.
The broker currently has a target price of 44 pence for the stock, however, it may want to update it after the companys share price rose from 28 pence to 56 pence this afternoon.
However, Collins Stewart noted in todays report that its valuation only presently ascribes partial value to 1 venture. The broker added that the success of any of the opportunities in its venture portfolio would highlight significant upside optionality in the Groups current share price.
Many investors following Angle agreed, noting that even after the increase, the company still has a market cap of 20 million, which, in their opinion, does not reflect the commercial potential of Parsortix.
http://www.proactiveinvestors.co.uk/companies/news/33689/wednesdays-most-followed-man-group-red-emperor-resources-dominos-pizza-angle-plc-33689.html
gibby - 28 Sep 2011 21:02 - 82 of 195
hi macho ref 77 / 81 - you will note i only said consider selling to buy back later, which means keep an eye on level 2 - be sensible as opposed to greedy and if happy cash in - i did not say sell but only consider
gibby - 28 Sep 2011 21:11 - 83 of 195
anyhow - there were several reasons for that note because the buys were virtually all small p.i.s who followed the crowd - no major ii at all - some trades that have not been shown yet and the fact nobody really understands the significance - also the product only appears to capture on cancer cells NOT does capture all - the market for this is huge but this treatment if after 2013 actually works will only capture a % of this not all of it - and other major players out there - i still say seriously consider cashing in but weigh up all options and watch very closely before jumping out if anyone does - iis will not be interested at this price - that is the city chatter - will wait for the euphoria and sp to reverse maybe move a month or two down when everyone chasing other quick wins
serious well done to any in before the hike today and those who have taken a risk and have already got out at profit - and good lick if they are trying for more profit tomorrow by hanging on - pre-open tomorrow should be very interesting - will it be another + 100% tomorrow or -50%?
btw the target sp for this a few years ago has been in or around 170p - since then dilution and many more shares in circulation - consider all factors particulary ii take
one thing is for sure - this was serious good news today - may keep the sp up and some more north tomorrow but only in the short term imo
serious well done to any in before the hike today and those who have taken a risk and have already got out at profit - and good lick if they are trying for more profit tomorrow by hanging on - pre-open tomorrow should be very interesting - will it be another + 100% tomorrow or -50%?
btw the target sp for this a few years ago has been in or around 170p - since then dilution and many more shares in circulation - consider all factors particulary ii take
one thing is for sure - this was serious good news today - may keep the sp up and some more north tomorrow but only in the short term imo
gibby - 29 Sep 2011 09:24 - 84 of 195
just looked at this - poor inexperienced sods early this morning who paid far too much - price is still to high dont get locked in imo
gla
gla
mitzy - 29 Sep 2011 09:53 - 85 of 195
Thanks for that gibby.
machoman - 29 Sep 2011 11:16 - 86 of 195
do not thank too early, it went to 79p this morning, and with a market well down, you have to expect taders taking profits.
is now on the way up again, and looks strong enough to go places
is now on the way up again, and looks strong enough to go places
machoman - 29 Sep 2011 11:25 - 87 of 195
AGL
Newspapers Guardian .........
Newspapers Guardian .........
But the day's standout performer was Aim-listed Angle, up 129% to 64.25p after it said a cell separation device from its Parsortix division could be used to isolate and capture very small numbers of cancer cells from blood. It is in discussions about the device with a number of cancer research institutes. Collins Stewart said:
We see this as not just a major validation of the Parsortix technology, but a significant broadening of Angle's commercial opportunity. Parsortix is aiming to seek both FDA approval and European CE mark accreditation by mid 2013. Such approvals would open up multi billion dollar clinical markets including cancer detection and monitoring, in addition to the immediate market available for research purposes. By this point, we would anticipate Parsortix to have attracted commercial interest from majors.
guardian
----------------
Technology firm Angle has announced that Parsortix, its 85% owned portfolio company which specialises in medical diagnostics, has achieved a major milestone by validating that its cell separation device can capture cancer cells added to blood.
Parsortix's patented cell separation device can be used, on a reproducible basis, to isolate and capture very small numbers of cancer cells from whole blood, Angle reports.
The device appears to efficiently capture all of the cancer cells, avoiding the risk of failing to detect cancer cells present in a blood sample.
It allows the identification of cancer cells within the device, without requiring a complicated cell extraction process and does not require the use of expensive and sometimes unreliable antibody affinity capture technology to isolate the cancer cells.
Angle said: "The company has already established discussions with several of the world's leading cancer research institutes and there is strong interest in such a product, which would not require regulatory approval for use for research purposes. The target is to establish sales of the product for research purposes as early as the second half of 2012.
"There is also the potential for a corporate partnership with one or more of the largest global medical diagnostic companies and initial discussions have identified encouraging interest in a commercial collaboration. This will be explored further over the coming months."
The group added: "There are major clinical markets for a simple CTC [circulating tumour cells] counting product estimated to exceed $4 bn per annum in the United States market alone. The target is to seek FDA [Food and Drug Administration] approval and European CE Mark by mid 2013 enabling sales of product for clinical use."
The CE mark is a mandatory conformity mark for products marketed in the European Union.
livecharts - Angle-announces-new-cancer-detection-device-
--------------
The junior AIM market provided the major fireworks with shares of technology firm Angle soaring to an all-time high of 66p before closing 36.25p or 129 per cent higher at 64.25p. Buyers piled in on hearing that Parsortix, its 85 per cent owned portfolio company which specialises in medical diagnostics, has achieved a major milestone by validating that its cell separation device can capture cancer cells added to blood.
Angle has already had discussions with several of the world cancer research institutes and there is also the potential for a corporate partnership with one or more of the largest global medical diagnostic companies.
Read more: this is money - MARKET-REPORT
dreamcatcher
- 29 Sep 2011 11:44
- 88 of 195
Good call gibby
machoman - 29 Sep 2011 11:56 - 89 of 195
re - dreamcatcher - 29 Sep 2011 11:44 - 88 of 88
Good call gibby
I wonder if you follow the stock, sell at 56p and missed of the way to 79p
Good call gibby
I wonder if you follow the stock, sell at 56p and missed of the way to 79p
machoman - 29 Sep 2011 12:03 - 90 of 195
re - gibby - 28 Sep 2011 21:02 - 82 of 88
hi macho ref 77 / 81 - you will note i only said consider selling to buy back later, which means keep an eye on level 2 - be sensible as opposed to greedy and if happy cash in - i did not say sell but only consider
that is not what you said, just read it again and stop to cover you bad sugestion.
Any stock with a large rise and large volume will have another day of rise if is two before profit taking is recomended. On small stocks is very difficult to sell and buy back on the same day as MMs use tricks and large spreads, many try it yesterday and had to pay higher price.
gibby - 28 Sep 2011 12:51 - 75 of 91
re - those in before today's hike should consider selling and buying back later!!! :-))))
hi macho ref 77 / 81 - you will note i only said consider selling to buy back later, which means keep an eye on level 2 - be sensible as opposed to greedy and if happy cash in - i did not say sell but only consider
that is not what you said, just read it again and stop to cover you bad sugestion.
Any stock with a large rise and large volume will have another day of rise if is two before profit taking is recomended. On small stocks is very difficult to sell and buy back on the same day as MMs use tricks and large spreads, many try it yesterday and had to pay higher price.
gibby - 28 Sep 2011 12:51 - 75 of 91
re - those in before today's hike should consider selling and buying back later!!! :-))))
dreamcatcher
- 29 Sep 2011 12:04
- 91 of 195
Machoman its a very good stock. Wish I did have it. gl
gibby - 29 Sep 2011 13:32 - 92 of 195
lol macho - i said consider sell to buy back not sell read it again - you twisted my words a tad there :-))
however today's low was 51p - high 70 odd pence - i think that speaks for itself - btw
you wont have any problem buying if quick enough
this for me now is one for the future more 2013 before seeing real increases to 3 figures here
pharma is not a cheap industry more funds will be needed and notoriously slow
momentum from p.i.s is all thats left for now here until further news imo
anyhow people could have top sliced remember
however today's low was 51p - high 70 odd pence - i think that speaks for itself - btw
you wont have any problem buying if quick enough
this for me now is one for the future more 2013 before seeing real increases to 3 figures here
pharma is not a cheap industry more funds will be needed and notoriously slow
momentum from p.i.s is all thats left for now here until further news imo
anyhow people could have top sliced remember
gibby - 29 Sep 2011 13:33 - 93 of 195
hi dc - seen similar to agl many time - even in recent times such as pym / phytopharm, pyc, sar etc - it will happen again
nothing wrong with agl but needs a reality check
hope you are having a good day
nothing wrong with agl but needs a reality check
hope you are having a good day
machoman - 29 Sep 2011 14:55 - 94 of 195
gibby
There is no LOL but BAD recomendation from you, you can twisted and turn it 1 million
times. ( if you do not sell how are you going to buy back )
The proof is on the pudding
at the time of saying it was 56p and went this morning to 79p.
re - however today's low was 51p
Your nonsence goes further as you do not know lows and highs of the day also
Missed this morning 23p ( 79 - 56p ) I gain 23p
retracement to 52p this morning you gain 4p ( if you say is time to buy back low of the day)
Just tell me who is right?
There is no LOL but BAD recomendation from you, you can twisted and turn it 1 million
times. ( if you do not sell how are you going to buy back )
The proof is on the pudding
at the time of saying it was 56p and went this morning to 79p.
re - however today's low was 51p
Your nonsence goes further as you do not know lows and highs of the day also
Missed this morning 23p ( 79 - 56p ) I gain 23p
retracement to 52p this morning you gain 4p ( if you say is time to buy back low of the day)
Just tell me who is right?
skinny
- 29 Sep 2011 15:07
- 95 of 195
Here we go again :-)
gibby - 29 Sep 2011 15:43 - 96 of 195
well i did say consider - no more
i didnt say - this is a strong sell get out now and buy later - i said consider it is that simple
i didnt say - this is a strong sell get out now and buy later - i said consider it is that simple
gibby - 29 Sep 2011 15:43 - 97 of 195
and i still say it as you may also want to consider buying now to sell later - lol!! then again you might not
machoman - 29 Sep 2011 15:51 - 98 of 195
I hope someone is not ......... Full as a tick
or maybe ....................Fur coat and no knickers
after all maybe ............The game/the cake is not worth the candle
some need .............. Get one's act together
allways trying to ........ Get a second bite/ two bites at the cherry
too many .....................Shilly-shally
it allways could be ...............Silver lining
or maybe ....................Fur coat and no knickers
after all maybe ............The game/the cake is not worth the candle
some need .............. Get one's act together
allways trying to ........ Get a second bite/ two bites at the cherry
too many .....................Shilly-shally
it allways could be ...............Silver lining
gibby - 29 Sep 2011 20:57 - 99 of 195
macho i hope you made some money here but personally would not want to be hanging around here - this is as i repeat one for the future and next good news rns - iis will purchase once the sp has dropped again - should hit sub 40 in the coming months with ease - no disrespect to the company just the way it is - todays volume was relatively low compared to yesterdays highs - best not to look at the sp - volumes far more important - that is a fact and gl
machoman - 30 Sep 2011 08:35 - 100 of 195
The marked down at the start, has encourage buyers and is bouncing back fast
54.50p was the lowest price paid on the bounce back.
Moneyam trades gives 81k buys for 48K sells, and yet is down so far.
54.50p was the lowest price paid on the bounce back.
Moneyam trades gives 81k buys for 48K sells, and yet is down so far.
machoman - 30 Sep 2011 10:12 - 101 of 195
The buyers are having a good fun to the MMs games and the last one was a large one 25K @ 62p ( 5 times NMS )
moneyam, as usual nothing goes right so chart from others
moneyam, as usual nothing goes right so chart from others
machoman - 30 Sep 2011 11:34 - 102 of 195
64.75p +5p
Merchant Securities Initiation Note on ANGLE - 119p price target
Parsortix delivery on capturing CTCs
ANGLE has been making substantial progress since its last fundraising
and, in our view, is poised to deliver on a number of fronts.
Recent demand for the Geomerics Enlighten platform is picking
up, with an exciting picture building in Parsortix, in particular. We
look forward to news flow in the coming months and initiate
coverage on the stock with a BUY rating and 119p price target.
The validation work successfully conducted by Parsortix has demonstrated that
the device it is developing can be used (reproducibly) to isolate and capture small
numbers of cancer cells from whole blood. The device has apparently captured all
of the cancer cells present in blood used in the experiments. We believe that this
achievement and milestone will enable the characterisation of cancer cells within
the device, without the need to extract them or use of the complex assay based
approach of the main competitor technology.
This potential breakthrough could open up a large market opportunity for Parsortix
with opportunities for early revenues through the launch of a research use device.
# We believe that the Parsortix technology has strong value as an applied research
tool, which could be followed by a number of different clinical applications.
#The risks to our investment thesis relate to the failure of one or more technologies
in the various venture businesses and a decline in the revenues derived from the
management-consulting business.
# We initiate coverage of ANGLE with a BUY rating and a target price of 119p,
driven by a sum-of-the-parts valuation of the constituent components of the
business.
Merchant Securities Initiation Note on ANGLE - 119p price target
Parsortix delivery on capturing CTCs
ANGLE has been making substantial progress since its last fundraising
and, in our view, is poised to deliver on a number of fronts.
Recent demand for the Geomerics Enlighten platform is picking
up, with an exciting picture building in Parsortix, in particular. We
look forward to news flow in the coming months and initiate
coverage on the stock with a BUY rating and 119p price target.
The validation work successfully conducted by Parsortix has demonstrated that
the device it is developing can be used (reproducibly) to isolate and capture small
numbers of cancer cells from whole blood. The device has apparently captured all
of the cancer cells present in blood used in the experiments. We believe that this
achievement and milestone will enable the characterisation of cancer cells within
the device, without the need to extract them or use of the complex assay based
approach of the main competitor technology.
This potential breakthrough could open up a large market opportunity for Parsortix
with opportunities for early revenues through the launch of a research use device.
# We believe that the Parsortix technology has strong value as an applied research
tool, which could be followed by a number of different clinical applications.
#The risks to our investment thesis relate to the failure of one or more technologies
in the various venture businesses and a decline in the revenues derived from the
management-consulting business.
# We initiate coverage of ANGLE with a BUY rating and a target price of 119p,
driven by a sum-of-the-parts valuation of the constituent components of the
business.
gibby - 30 Sep 2011 12:14 - 103 of 195
had a quick day trade myself here earlier today - easy cash - hope others did also - but i do not intend hanging around despite broker note - this afternoon will be very telling after around 3pm - gla - good luck if anyone stays the course beyond today
mitzy - 30 Sep 2011 12:58 - 104 of 195
Incredible share(not a holder) but will watch.
gibby - 30 Sep 2011 13:00 - 105 of 195
lol in for another day trade i must be bonkers - seeking 80p! yeeeehaaaaa!!! then out 75p will do!!!
gibby - 30 Sep 2011 13:31 - 106 of 195
interesting
Resistance 2 103.2
Resistance 1 70.67
relatively low volume shares in circulation
Resistance 2 103.2
Resistance 1 70.67
relatively low volume shares in circulation
HARRYCAT
- 30 Sep 2011 13:32
- 107 of 195
I'm same as you mitzy. Just watching from the sidelines, but seems to be trading momentum causing the bounces now and dangerous territory, imo.
gibby - 30 Sep 2011 13:46 - 108 of 195
agreed hc - i have ducked out of my second day trade here at break even - not looking so good at all now - the other main worry is that these are mainly small trades against a relatively low voulme - hence quick swings - i dont want to be on the one going in the wrong direction - hope you are having a good day s and otherwise
dreamcatcher
- 30 Sep 2011 13:46
- 109 of 195
Well done
gibby - 30 Sep 2011 13:48 - 110 of 195
cheers - rrl / rmp going well!!
machoman - 30 Sep 2011 14:44 - 111 of 195
gibby
Looking at the chart and times you are sugesting buying and selling, I am reaching the conclusion there are saying a few porkies.
As I told you yesterday, day trading does not work in this share, as eventualy one finishes paying more than the last sell.
If really true you did the first trade then the second, you did pay well up on the selling earlier and you finished on panicking and selling at a loss on the second trade. ( buying was around or over 70p ) and can see you are very carefull on no saying prices )
re - gibby - 30 Sep 2011 12:14 - 103 of 110
had a quick day trade myself here earlier today - easy cash - hope others did also
gibby - 30 Sep 2011 13:00 - 105 of 110
lol in for another day trade i must be bonkers - seeking 80p! yeeeehaaaaa!!! then out 75p will do!!!
gibby - 30 Sep 2011 13:46 - 108 of 110
agreed hc - i have ducked out of my second day trade here at break even
Looking at the chart and times you are sugesting buying and selling, I am reaching the conclusion there are saying a few porkies.
As I told you yesterday, day trading does not work in this share, as eventualy one finishes paying more than the last sell.
If really true you did the first trade then the second, you did pay well up on the selling earlier and you finished on panicking and selling at a loss on the second trade. ( buying was around or over 70p ) and can see you are very carefull on no saying prices )
re - gibby - 30 Sep 2011 12:14 - 103 of 110
had a quick day trade myself here earlier today - easy cash - hope others did also
gibby - 30 Sep 2011 13:00 - 105 of 110
lol in for another day trade i must be bonkers - seeking 80p! yeeeehaaaaa!!! then out 75p will do!!!
gibby - 30 Sep 2011 13:46 - 108 of 110
agreed hc - i have ducked out of my second day trade here at break even
HARRYCAT
- 30 Sep 2011 14:46
- 112 of 195
Ugh.......same old cr*p! Concentrate on your own trades and get a life.
machoman - 30 Sep 2011 14:57 - 113 of 195
HARRY have you lost you CAT?
There is one round the corner full of your SHEET
better feed ( it ) properly
( it ) is not a pussy
There is one round the corner full of your SHEET
better feed ( it ) properly
( it ) is not a pussy
machoman - 30 Sep 2011 14:58 - 114 of 195
MMs keeping it on a large spread so sellers can not get a good price, and buyers paying through the nose
gibby - 30 Sep 2011 20:56 - 115 of 195
macho i wont gratify that with a comment exceot you do not know either the time or qty of my trades - you only know the time i wrote on this bb about them
anyhow the next sp rns likely here is the games platform geometrics enlighten with parsortix further off i am reliably informed - remember so far parsortix only appears to do what is hoped as opposed to actually does - when the euphoria dies down here i might buy some to keep - no more day trades here for me - too volatile on small t/o against mainly low value pi qtys - iis will bide their time as i will now
anyhow the next sp rns likely here is the games platform geometrics enlighten with parsortix further off i am reliably informed - remember so far parsortix only appears to do what is hoped as opposed to actually does - when the euphoria dies down here i might buy some to keep - no more day trades here for me - too volatile on small t/o against mainly low value pi qtys - iis will bide their time as i will now
machoman - 03 Oct 2011 09:57 - 116 of 195
gibby
I have been on the business too long and much the same on the BB's, to know what people do. ( you just said it ...... i wont gratify that )
An I did notice others saying it much the same line...........
" I bought yesterday", or yes today was well up from the start. ( spending all day on the boards and saying it next day ) makes me laugh, when people believe their own porkies.
If you want to be serious or any one to believe you, say it when it happens otherwise keep it to yourself is my motto.
I have been on the business too long and much the same on the BB's, to know what people do. ( you just said it ...... i wont gratify that )
An I did notice others saying it much the same line...........
" I bought yesterday", or yes today was well up from the start. ( spending all day on the boards and saying it next day ) makes me laugh, when people believe their own porkies.
If you want to be serious or any one to believe you, say it when it happens otherwise keep it to yourself is my motto.
machoman - 03 Oct 2011 10:21 - 117 of 195
close, only managed to get 75% profit on less than 4 days
required field - 25 Oct 2011 09:19 - 118 of 195
Looking like a good'un this one.....
required field - 26 Oct 2011 08:54 - 119 of 195
I'm a bit of a latecomer in this but it seems to have some woooshh in it...steady rise every day...
required field - 27 Oct 2011 09:17 - 120 of 195
Up again with it's daily rise....
required field - 28 Oct 2011 10:55 - 121 of 195
Flying this morning....shares mag tip yesterday....
required field - 31 Oct 2011 08:19 - 122 of 195
Some sort of nobel prize has been awarded to a company director...bravo !....
required field - 01 Nov 2011 08:31 - 123 of 195
Hefty profit taking today....luckily I did so yesterday.....
riviera1069 - 07 Nov 2011 23:04 - 124 of 195
SMALL CAPS FOCUS: Sum of its parts could make ANGLE a good investmentBy Ian Lyall, Proactive Investors
Last updated at 2:57 PM on 7th November 2011
Comments (0) Share ANGLE is the longest established of the intellectual property groups quoted on the London market, and its share price rocketed recently when the group revealed one of its companies successfully tested a device that could change forever the way cancer is treated and monitored.
However there is more to ANGLE than just Parsortix, the firm hoping for that medical breakthrough. It has two other leading investments, while there is a potential payout from a third which is currently the subject of a bitter legal wrangle.
Founded in 1994, ANGLE listed a decade later. Unlike other intellectual property groups, ANGLE does not invest in other peoples businesses.
Break through: Parsortix's device promises huge improvement in the way chemotherapy is administered
Instead it founds, owns, operates and invests in its own businesses from the ground up.
Chief executive Andrew Newland says this enables the company to build stronger, more robust businesses with a lower failure rate and risk profile than traditional investor models.
Parsortix (90 per cent owned by ANGLE)
The jewel in the crown of the business, it has come up with a small, devilishly simple separation device that has the potential to capture and characterise cancer cells in the bloodstream.
This of course has all sorts of ramifications for the way the disease is treated and monitored.
For a start it may be possible using the device to determine which treatments are working, and which are not. Now this promises a huge improvement in the way chemotherapy is administered.
The device also has the potential to monitor patients in remission, and to pick up early signs of the return of the cancer, ahead of the patient experiencing any symptoms. The earlier the treatment, the greater the likelihood the patient will survive. Furthermore, it may be possible to develop a simple blood test to provide routine screening of healthy people to check for early signs of cancer ahead of any symptoms.
This is a step on from the existing means of identifying circulating cancer cells, where tests are specific to each cancer type.
'We think ours has a much more universal application - hopefully to all solid tumours,' says Newland.
The potential clinical market is conservatively estimated by the company to be worth around $4billion annually in the United States alone.
More...SMALL CAP MOVERS: Aim stocks stoic amid Greek crisis and MF Global bankruptcy
SMALL CAP MOVERS: AIM boosted by positive events in broader market
Novocellus (82 per cent holding)
Its EmbryoSure selection system has the potential to revolutionise in-vitro fertilisation.
'We believe EmbryoSure will identify with 95 per cent confidence which one of the embryos is likely to be a top quartile embryo,' says Newland.
Currently there is no such means of identifying the best eggs. Novocellus reckons EmbryoSure has the potential to increase pregnancy rates by a quarter and possibly by as much as 40 per cent.
If EmbryoSure reduces the number of cycles of IVF required to get pregnant, the overall IVF cost will fall. And having a way of spotting 'top quartile' eggs would aid the transition to single embryo transfer, which the healthcare system is pushing for.
'We believe there is going to be a regulatory drive behind our product,' Newland adds.
Geomerics (33 per cent holding)
According to commentators the Electronic Arts shoot em up Battlefield 3 could knock current PlayStation and X-Box number one Call of Duty off its perch.
For Geomerics it is a huge opportunity to showcase its Enlighten middleware, and turn it into the industry standard for top quality computer games' lighting and graphics.
'We are nearly at the stage where the sales income not only covers the operating costs we have been at that level for a while but also the development costs and overheads,' says Newland.
It has a 2.3million development deal with a large, but unnamed technology company.
Acolyte Biomedica
The very first company ANGLE set up, the business was sold to the American giant 3M in 2007 in a deal brokered by Porton Capital, Acolytes biggest shareholder at exit. Porton is currently locked in a court battle over proceeds still owed. If successful then it paves the way for ANGLE to claim back up to 4.7million.
What the City Says
The share price, currently 80.5p, is nearly double the last documented price target from Collins Stewart and is closing in on the 119p valuation placed on the stock by Merchant Securities.
'We have been encouraged by updates on several of its venture companies, including Geomerics and Parsortix,' said Merchant analyst Navid Malik in a note to clients. We see calendar 2012 as a key year, which could show the signs of significant delivery on commercial deals and progress within a number of the subsidiary businesses.
Read more: http://www.thisismoney.co.uk/money/markets/article-2058566/SMALL-CAPS-FOCUS-Sum-parts-make-ANGLE-good-investment.html#ixzz1d40IIOE9
Last updated at 2:57 PM on 7th November 2011
Comments (0) Share ANGLE is the longest established of the intellectual property groups quoted on the London market, and its share price rocketed recently when the group revealed one of its companies successfully tested a device that could change forever the way cancer is treated and monitored.
However there is more to ANGLE than just Parsortix, the firm hoping for that medical breakthrough. It has two other leading investments, while there is a potential payout from a third which is currently the subject of a bitter legal wrangle.
Founded in 1994, ANGLE listed a decade later. Unlike other intellectual property groups, ANGLE does not invest in other peoples businesses.
Break through: Parsortix's device promises huge improvement in the way chemotherapy is administered
Instead it founds, owns, operates and invests in its own businesses from the ground up.
Chief executive Andrew Newland says this enables the company to build stronger, more robust businesses with a lower failure rate and risk profile than traditional investor models.
Parsortix (90 per cent owned by ANGLE)
The jewel in the crown of the business, it has come up with a small, devilishly simple separation device that has the potential to capture and characterise cancer cells in the bloodstream.
This of course has all sorts of ramifications for the way the disease is treated and monitored.
For a start it may be possible using the device to determine which treatments are working, and which are not. Now this promises a huge improvement in the way chemotherapy is administered.
The device also has the potential to monitor patients in remission, and to pick up early signs of the return of the cancer, ahead of the patient experiencing any symptoms. The earlier the treatment, the greater the likelihood the patient will survive. Furthermore, it may be possible to develop a simple blood test to provide routine screening of healthy people to check for early signs of cancer ahead of any symptoms.
This is a step on from the existing means of identifying circulating cancer cells, where tests are specific to each cancer type.
'We think ours has a much more universal application - hopefully to all solid tumours,' says Newland.
The potential clinical market is conservatively estimated by the company to be worth around $4billion annually in the United States alone.
More...SMALL CAP MOVERS: Aim stocks stoic amid Greek crisis and MF Global bankruptcy
SMALL CAP MOVERS: AIM boosted by positive events in broader market
Novocellus (82 per cent holding)
Its EmbryoSure selection system has the potential to revolutionise in-vitro fertilisation.
'We believe EmbryoSure will identify with 95 per cent confidence which one of the embryos is likely to be a top quartile embryo,' says Newland.
Currently there is no such means of identifying the best eggs. Novocellus reckons EmbryoSure has the potential to increase pregnancy rates by a quarter and possibly by as much as 40 per cent.
If EmbryoSure reduces the number of cycles of IVF required to get pregnant, the overall IVF cost will fall. And having a way of spotting 'top quartile' eggs would aid the transition to single embryo transfer, which the healthcare system is pushing for.
'We believe there is going to be a regulatory drive behind our product,' Newland adds.
Geomerics (33 per cent holding)
According to commentators the Electronic Arts shoot em up Battlefield 3 could knock current PlayStation and X-Box number one Call of Duty off its perch.
For Geomerics it is a huge opportunity to showcase its Enlighten middleware, and turn it into the industry standard for top quality computer games' lighting and graphics.
'We are nearly at the stage where the sales income not only covers the operating costs we have been at that level for a while but also the development costs and overheads,' says Newland.
It has a 2.3million development deal with a large, but unnamed technology company.
Acolyte Biomedica
The very first company ANGLE set up, the business was sold to the American giant 3M in 2007 in a deal brokered by Porton Capital, Acolytes biggest shareholder at exit. Porton is currently locked in a court battle over proceeds still owed. If successful then it paves the way for ANGLE to claim back up to 4.7million.
What the City Says
The share price, currently 80.5p, is nearly double the last documented price target from Collins Stewart and is closing in on the 119p valuation placed on the stock by Merchant Securities.
'We have been encouraged by updates on several of its venture companies, including Geomerics and Parsortix,' said Merchant analyst Navid Malik in a note to clients. We see calendar 2012 as a key year, which could show the signs of significant delivery on commercial deals and progress within a number of the subsidiary businesses.
Read more: http://www.thisismoney.co.uk/money/markets/article-2058566/SMALL-CAPS-FOCUS-Sum-parts-make-ANGLE-good-investment.html#ixzz1d40IIOE9
riviera1069 - 11 Nov 2011 17:38 - 125 of 195
Nice rise on the back of this latest announcement!!
For immediate release
11 November 2011
ANGLE plc ("the Company")
Parsortix Update
VALIDATION FOR PROSTATE CANCER
ANGLE plc (AIM : AGL) is delighted to announce that Parsortix Inc ("Parsortix"), its 90% owned portfolio company which specialises in medical diagnostics has achieved another important milestone by confirming that its cell separation device can capture prostate cancer cells.
ANGLE has previously established that its Parsortix separation technology can capture breast cancer cells added to blood. New experiments have now shown that the Parsortix separation technology works equally well with cultured prostate cancer cells added to blood.
This new validation is an important step towards demonstrating that, unlike existing antibody affinity based technology, the Parsortix separation technology works well with any solid tumour cancers without the need for modification.
The Parsortix separation technology offers the potential for a CTC (circulating tumour cell) isolation, capture and characterisation device, for:
early detection of cancer;
monitoring of cancer patients during treatment; and
post-treatment monitoring of cancer patients in remission.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"The successful capture and identification of prostate cancer cells added to blood further substantiates the potential for the Parsortix separation technology to become a market-leading product, which is simple, effective and affordable."
For further information:
ANGLE plc
01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Adrian Hargrave (Nominated adviser)
Andy Roberts (Sales)
020 7397 8900
Buchanan
Lisa Baderoon
020 7466 5000
Scott Harris
Stephen Scott, James O'Shaughnessy, Harry Dee
0207 653 0030
For immediate release
11 November 2011
ANGLE plc ("the Company")
Parsortix Update
VALIDATION FOR PROSTATE CANCER
ANGLE plc (AIM : AGL) is delighted to announce that Parsortix Inc ("Parsortix"), its 90% owned portfolio company which specialises in medical diagnostics has achieved another important milestone by confirming that its cell separation device can capture prostate cancer cells.
ANGLE has previously established that its Parsortix separation technology can capture breast cancer cells added to blood. New experiments have now shown that the Parsortix separation technology works equally well with cultured prostate cancer cells added to blood.
This new validation is an important step towards demonstrating that, unlike existing antibody affinity based technology, the Parsortix separation technology works well with any solid tumour cancers without the need for modification.
The Parsortix separation technology offers the potential for a CTC (circulating tumour cell) isolation, capture and characterisation device, for:
early detection of cancer;
monitoring of cancer patients during treatment; and
post-treatment monitoring of cancer patients in remission.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"The successful capture and identification of prostate cancer cells added to blood further substantiates the potential for the Parsortix separation technology to become a market-leading product, which is simple, effective and affordable."
For further information:
ANGLE plc
01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Adrian Hargrave (Nominated adviser)
Andy Roberts (Sales)
020 7397 8900
Buchanan
Lisa Baderoon
020 7466 5000
Scott Harris
Stephen Scott, James O'Shaughnessy, Harry Dee
0207 653 0030
riviera1069 - 16 Nov 2011 16:45 - 126 of 195
For immediate release
16 November 2011
ANGLE plc ("the Company")
Novocellus Update
ANGLE plc (AIM:AGL) provides an update on Novocellus, its 82% owned portfolio company which specialises in IVF embryo viability.
Novocellus has a partnership with Origio, a leading supplier of IVF culture medium, whereby Origio are responsible for undertaking the final trials for Novocellus' embryo viability product, EmbryoSure. Origio then have the right to license the EmbryoSure IP in exchange for milestone payments and a 25% royalty on future sales.
As previously advised to the market, the trial of EmbryoSure is delayed. The timeframe for completing the trials is at present uncertain. ANGLE is meeting with Origio at the end of this month to review options for progressing the trials. ANGLE remains confident of the potential for EmbryoSure to make a major impact in the IVF market.
A further announcement will be made once the position becomes clearer.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"We continue to believe that EmbryoSure has the potential to make a major impact in the IVF market and it is important to us that we get the trials completed and the product in the market as quickly as possible."
For further information:
ANGLE plc
01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Adrian Hargrave (Nominated adviser)
Andy Roberts (Sales)
020 7397 8900
Buchanan
Lisa Baderoon
020 7466 5000
Scott Harris
Stephen Scott, Harry Dee
0207 653 0030
required field - 16 Dec 2011 09:19 - 127 of 195
This is starting to look very good indeed considering the low market cap....
riviera1069 - 19 Jan 2012 09:36 - 128 of 195
RNS
RNS Number : 8087V
Angle PLC
19 January 2012
For Immediate Release
19 January 2012
ANGLE plc
("ANGLE" or the "Company")
Notice of Interim Results and Webcast - 26 January 2012
ANGLE plc (AIM: AGL) is pleased to announce that it will be releasing its interim results for the six months ended 31 October 2011 on Thursday 26 January 2012.
The interim results presentation will be given by Andrew Newland, Chief Executive Officer and Ian Griffiths, Finance Director.
Meetings
A meeting for analysts will be held at 10:00am on the morning of the results announcement at the offices of Buchanan Communications, 107 Cheapside, London EC2V 6DN.
A lunch meeting for Private Client Brokers will follow commencing at 12:30pm.
Webcast Details
Running in parallel with the analyst meeting will be a live webcast. Please log on 10 minutes before the start of the webcast at (09:50am GMT). The webcast log on address is:http://mediaserve.buchanan.uk.com/2012/angle260112/registration.asp.
A recording of the webcast will also be made available on ANGLE's website (www.ANGLEplc.com) following the results meeting.
For further information:
ANGLE plc
01483 685830
Andrew Newland, Chief Executive Officer
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Adrian Hargrave (Nominated adviser)
Andy Roberts (Sales)
020 7397 8900
Buchanan
Lisa Baderoon
020 7466 5000 / 07721 413 496
Scott Harris
Stephen Scott, Harry Dee
020 7653 0030
RNS Number : 8087V
Angle PLC
19 January 2012
For Immediate Release
19 January 2012
ANGLE plc
("ANGLE" or the "Company")
Notice of Interim Results and Webcast - 26 January 2012
ANGLE plc (AIM: AGL) is pleased to announce that it will be releasing its interim results for the six months ended 31 October 2011 on Thursday 26 January 2012.
The interim results presentation will be given by Andrew Newland, Chief Executive Officer and Ian Griffiths, Finance Director.
Meetings
A meeting for analysts will be held at 10:00am on the morning of the results announcement at the offices of Buchanan Communications, 107 Cheapside, London EC2V 6DN.
A lunch meeting for Private Client Brokers will follow commencing at 12:30pm.
Webcast Details
Running in parallel with the analyst meeting will be a live webcast. Please log on 10 minutes before the start of the webcast at (09:50am GMT). The webcast log on address is:http://mediaserve.buchanan.uk.com/2012/angle260112/registration.asp.
A recording of the webcast will also be made available on ANGLE's website (www.ANGLEplc.com) following the results meeting.
For further information:
ANGLE plc
01483 685830
Andrew Newland, Chief Executive Officer
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Adrian Hargrave (Nominated adviser)
Andy Roberts (Sales)
020 7397 8900
Buchanan
Lisa Baderoon
020 7466 5000 / 07721 413 496
Scott Harris
Stephen Scott, Harry Dee
020 7653 0030
riviera1069 - 23 Jan 2012 11:53 - 129 of 195
RNS Number : 9682V
Angle PLC
23 January 2012
For immediate release
23 January 2012
ANGLE plc ("the Company")
Parsortix Update
CAPTURE OF CIRCULATING TUMOUR CELLS (CTCs) IN CANCER PATIENT BLOOD
ANGLE plc (AIM: AGL) is delighted to announce that Parsortix Inc ("Parsortix"), its 90% owned portfolio company which specialises in medical diagnostics has achieved a major milestone by using its cell separation device to successfully capture circulating tumour cells (CTCs) in cancer patient blood.
ANGLE has previously established that its Parsortix separation technology can capture cultured breast cancer cells, prostate cancer cells and lung cancer cells added to blood (spiked blood). However until now, the Parsortix separation technology had not been proven to capture CTCs in actual cancer patient blood. This is significant as actual cancer patient blood would be expected to contain only a very small number of CTCs in the sample (if any), as well as potential issues due to patient disease factors adversely affecting the performance of the separation technology.
Working in the University of Surrey's oncology department, and utilising their access to cancer patient blood, the Parsortix team has undertaken a series of small volume 1ml separations of the blood of late stage prostate cancer patients. The blood has passed successfully through the device with similar characteristics to the spiked healthy blood and in a number of separations captured tumour cells were clearly identified and confirmed by the University of Surrey's oncology team. The results compare favourably with the existing FDA approved antibody-based capture technology.
The experimental findings to date are encouraging and support the potential to develop a successful research and clinical cancer diagnostic product.
Development of the Parsortix separation technology is proceeding to plan and we are on track with the next key milestones, which are:
· Validation of the separation device for other cancer types, particularly those where the existing antibody affinity capture technology is unable to capture CTCs, such as ovarian cancer;
· The optimisation of the separation device to allow its easy use in the laboratory addressing critical factors of increasing the volume of blood that can be screened and the speed of blood flow through the device; and
· Independent third party validation of the performance of the Parsortix CTC separation device by leading cancer research centres.
The Parsortix separation technology offers the potential for a CTC isolation, capture and characterisation device, irrespective of cancer type for:
· Early detection of cancer;
· Monitoring of cancer patients during treatment; and
· Post-treatment monitoring of cancer patients in remission.
It may be possible to use the captured CTCs for molecular profiling to help define tumour biology and risk of progression.
Parsortix Founder and Chief Technology Officer, Dr George Hvichia, commented:
"We are very enthusiastic to have worked with our first outside collaborative team to achieve the first independent validation of clinical CTC isolation in our device by a leading cancer research centre."
Head of the University of Surrey Oncology Department, Professor Hardev Pandha, commented:
"The University of Surrey is delighted to be working with ANGLE on this novel approach to CTC capture. Effective monitoring of the level of CTCs in patients' blood offers great potential for the improvement of cancer treatment."
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"The successful capture of CTCs in cancer patient blood is a tremendous step forward towards our goal of establishing the Parsortix separation technology as a market-leading product, which is simple, effective and affordable."
For further information:
ANGLE plc
01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Angle PLC
23 January 2012
For immediate release
23 January 2012
ANGLE plc ("the Company")
Parsortix Update
CAPTURE OF CIRCULATING TUMOUR CELLS (CTCs) IN CANCER PATIENT BLOOD
ANGLE plc (AIM: AGL) is delighted to announce that Parsortix Inc ("Parsortix"), its 90% owned portfolio company which specialises in medical diagnostics has achieved a major milestone by using its cell separation device to successfully capture circulating tumour cells (CTCs) in cancer patient blood.
ANGLE has previously established that its Parsortix separation technology can capture cultured breast cancer cells, prostate cancer cells and lung cancer cells added to blood (spiked blood). However until now, the Parsortix separation technology had not been proven to capture CTCs in actual cancer patient blood. This is significant as actual cancer patient blood would be expected to contain only a very small number of CTCs in the sample (if any), as well as potential issues due to patient disease factors adversely affecting the performance of the separation technology.
Working in the University of Surrey's oncology department, and utilising their access to cancer patient blood, the Parsortix team has undertaken a series of small volume 1ml separations of the blood of late stage prostate cancer patients. The blood has passed successfully through the device with similar characteristics to the spiked healthy blood and in a number of separations captured tumour cells were clearly identified and confirmed by the University of Surrey's oncology team. The results compare favourably with the existing FDA approved antibody-based capture technology.
The experimental findings to date are encouraging and support the potential to develop a successful research and clinical cancer diagnostic product.
Development of the Parsortix separation technology is proceeding to plan and we are on track with the next key milestones, which are:
· Validation of the separation device for other cancer types, particularly those where the existing antibody affinity capture technology is unable to capture CTCs, such as ovarian cancer;
· The optimisation of the separation device to allow its easy use in the laboratory addressing critical factors of increasing the volume of blood that can be screened and the speed of blood flow through the device; and
· Independent third party validation of the performance of the Parsortix CTC separation device by leading cancer research centres.
The Parsortix separation technology offers the potential for a CTC isolation, capture and characterisation device, irrespective of cancer type for:
· Early detection of cancer;
· Monitoring of cancer patients during treatment; and
· Post-treatment monitoring of cancer patients in remission.
It may be possible to use the captured CTCs for molecular profiling to help define tumour biology and risk of progression.
Parsortix Founder and Chief Technology Officer, Dr George Hvichia, commented:
"We are very enthusiastic to have worked with our first outside collaborative team to achieve the first independent validation of clinical CTC isolation in our device by a leading cancer research centre."
Head of the University of Surrey Oncology Department, Professor Hardev Pandha, commented:
"The University of Surrey is delighted to be working with ANGLE on this novel approach to CTC capture. Effective monitoring of the level of CTCs in patients' blood offers great potential for the improvement of cancer treatment."
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"The successful capture of CTCs in cancer patient blood is a tremendous step forward towards our goal of establishing the Parsortix separation technology as a market-leading product, which is simple, effective and affordable."
For further information:
ANGLE plc
01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
riviera1069 - 23 Jan 2012 11:54 - 130 of 195
up 10% today - More to come Thursday I say
riviera1069 - 26 Jan 2012 18:50 - 131 of 195
Well I was wrong and sold at a small profit today. Still think this will come good but todays RNS wasnt brilliant!!
skinny
- 14 Jan 2013 17:18
- 132 of 195
Just seen this.
;MA(50);MA(200)&IND=VOLMA(60);RSI(14)&Layout=2Line;Default;Price;HisDate&XCycle=&XFormat=)
PARSORTIX CELL RECOVERY
ANGLE plc (AIM: AGL), the specialist medtech company, is delighted to announce that the Company has achieved a major new breakthrough in the potential use of its Parsortix non-invasive cancer diagnostic product.
In addition to the technology's ability to capture and count very rare circulating tumour cells (CTCs) from the blood of cancer patients, ANGLE has developed a process for recovering captured cells from the Parsortix cassette.
This recovery capability gives the potential for the cells captured by the Parsortix cassette to be analysed by a variety of contemporary molecular techniques. Enabling CTC analysis using these techniques substantially extends the Parsortix technology's capability, opens up many new diagnostic, prognostic and treatment applications for cancer patients, and greatly increases the size of the market available to ANGLE.
There is no device currently in the market designed to recover CTCs and as a result there is a major unmet medical need. Of the various systems known to be under development, a major differentiator of the Parsortix technology is that it offers the potential to recover intact, living cells.
Analysis of CTCs can be used to screen and diagnose patients and importantly to monitor response to treatment in a non-invasive manner without having to perform a tumour biopsy. ANGLE's research partner, the Paterson Institute for Cancer Research, is a world leader in developing medical applications in this field and it will be investigating the potential for the Parsortix system to be used as a source of CTCs for these applications.
ANGLE's Founder and Chief Executive, Andrew Newland, commented:
"This major development means that our system now offers two approaches to analysis of CTCs: counting and identification of cells captured within the cassette; and molecular analysis of cells recovered from the cassette as a liquid biopsy. We know from discussions with researchers and physicians that there is market demand for this versatility."
ANGLE plc (AIM: AGL), the specialist medtech company, is delighted to announce that the Company has achieved a major new breakthrough in the potential use of its Parsortix non-invasive cancer diagnostic product.
In addition to the technology's ability to capture and count very rare circulating tumour cells (CTCs) from the blood of cancer patients, ANGLE has developed a process for recovering captured cells from the Parsortix cassette.
This recovery capability gives the potential for the cells captured by the Parsortix cassette to be analysed by a variety of contemporary molecular techniques. Enabling CTC analysis using these techniques substantially extends the Parsortix technology's capability, opens up many new diagnostic, prognostic and treatment applications for cancer patients, and greatly increases the size of the market available to ANGLE.
There is no device currently in the market designed to recover CTCs and as a result there is a major unmet medical need. Of the various systems known to be under development, a major differentiator of the Parsortix technology is that it offers the potential to recover intact, living cells.
Analysis of CTCs can be used to screen and diagnose patients and importantly to monitor response to treatment in a non-invasive manner without having to perform a tumour biopsy. ANGLE's research partner, the Paterson Institute for Cancer Research, is a world leader in developing medical applications in this field and it will be investigating the potential for the Parsortix system to be used as a source of CTCs for these applications.
ANGLE's Founder and Chief Executive, Andrew Newland, commented:
"This major development means that our system now offers two approaches to analysis of CTCs: counting and identification of cells captured within the cassette; and molecular analysis of cells recovered from the cassette as a liquid biopsy. We know from discussions with researchers and physicians that there is market demand for this versatility."
kimoldfield
- 14 Jan 2013 17:20
- 133 of 195
I missed that one too skinny! :o(
skinny
- 14 Jan 2013 17:21
- 134 of 195
Sounds good news though!
kimoldfield
- 14 Jan 2013 17:26
- 135 of 195
Very promising!
mitzy - 14 Jan 2013 19:30 - 136 of 195
Superb.
js8106455 - 30 Jan 2014 07:49 - 137 of 195
skinny
- 30 Jan 2014 07:56
- 138 of 195
Interim Results
Highlights in the year to date
· Balance sheet and specialist medtech focus strengthened by sale of Geomerics in December 2013 to ARM Holdings plc for up to £6.2 million in cash with £5.5 million already received
· Product development completed for the Parsortix system for both research and clinical use
· CE Mark authorisation secured for the Parsortix cell separation system for use as an in vitro diagnostic device in the European Union in the treatment of patients
· University of Surrey Oncology Group completed its validation of Parsortix technology, using colorectal cancer cells. The Parsortix system demonstrated twice the sensitivity of currently accepted clinical practice for CTC capture
· Cancer Research UK's Paterson Institute for Cancer Research identified key clinical advantages for the Parsortix system and has included Parsortix in its ongoing efforts to deliver personalised medicine
· Specialist, larger scale manufacturer appointed to manufacture the Parsortix system with the necessary quality systems and capacity to support roll out into the market
· Partnership with the Medical Research Council's Cancer Unit at the University of Cambridge to establish a Cambridge Parsortix Laboratory
· Appointment as a Scientific Adviser of Dr Harold Swerdlow, a world-leading expert in next generation sequencing (NGS) and Head of R&D at the Wellcome Trust Sanger Institute
· Loss for the half year of £0.5 million (H1 2013: loss £0.4 million)
· Cash balance at 31 October 2013 of £0.4 million (30 April 2013: £1.8 million). Cash position subsequently strengthened with the sale of Geomerics
Highlights in the year to date
· Balance sheet and specialist medtech focus strengthened by sale of Geomerics in December 2013 to ARM Holdings plc for up to £6.2 million in cash with £5.5 million already received
· Product development completed for the Parsortix system for both research and clinical use
· CE Mark authorisation secured for the Parsortix cell separation system for use as an in vitro diagnostic device in the European Union in the treatment of patients
· University of Surrey Oncology Group completed its validation of Parsortix technology, using colorectal cancer cells. The Parsortix system demonstrated twice the sensitivity of currently accepted clinical practice for CTC capture
· Cancer Research UK's Paterson Institute for Cancer Research identified key clinical advantages for the Parsortix system and has included Parsortix in its ongoing efforts to deliver personalised medicine
· Specialist, larger scale manufacturer appointed to manufacture the Parsortix system with the necessary quality systems and capacity to support roll out into the market
· Partnership with the Medical Research Council's Cancer Unit at the University of Cambridge to establish a Cambridge Parsortix Laboratory
· Appointment as a Scientific Adviser of Dr Harold Swerdlow, a world-leading expert in next generation sequencing (NGS) and Head of R&D at the Wellcome Trust Sanger Institute
· Loss for the half year of £0.5 million (H1 2013: loss £0.4 million)
· Cash balance at 31 October 2013 of £0.4 million (30 April 2013: £1.8 million). Cash position subsequently strengthened with the sale of Geomerics
required field - 30 Jan 2014 09:11 - 139 of 195
Down today...but this is a very promising company with huge potential if Parsortix gets adopted worldwide !....
skinny
- 18 Feb 2014 07:16
- 140 of 195
Parsortix Launch at Circulate Conference in Berlin
ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce that it is launching its Parsortix non-invasive cancer diagnostics system at the 4th Annual Circulate conference in Berlin on 19 and 20 February 2014.
Circulate is an annual conference for scientists, medical researchers, diagnostic and pharmaceutical companies pioneering the emerging field of circulating tumour cells (CTCs) and circulating cancer biomarkers.
At the conference, Mr Hari Nageswaran, a Clinical Research Fellow from the University of Surrey, will present initial data from a study entitled 'Use of a new size based CTC capture and harvest technology for colorectal cancer studies'. Mr Nageswaran used ANGLE's Parsortix system to carry out the study.
ANGLE's Parsortix system enables the capture of CTCs from cancer patient blood for mutational analysis. The Parsortix system uses a simple blood test to capture the cancer cells for analysis in contrast to the established solid tumour biopsy process where cells are surgically removed from the primary tumour. The Company's liquid biopsy has key medical advantages in that (i) being a simple blood test, it is non-invasive (ii) it can be used for inaccessible tumours where a solid biopsy is not possible or is very difficult and (iii) it can be repeated as often as required during the patient's treatment, which is important as the patient's cancer mutates over time.
Following ANGLE's successful deployment of the Parsortix system with key opinion leaders, and the Company's success in securing a CE Mark for the product, ANGLE is now making the Parsortix system available for sale to the European clinical market.
ANGLE's Founder and Chief Executive, Andrew Newland, commented:
"We believe that the ability of our patented Parsortix system to capture CTCs from patient blood opens a wide range of potential applications in treating cancer patients and we look forward to attending the Circulate conference and discussing that capability with key industry, medical and research players involved in personalised cancer care. We also look forward to Mr Nageswaran's presentation and his insight into the medical significance of the Parsortix system."
ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce that it is launching its Parsortix non-invasive cancer diagnostics system at the 4th Annual Circulate conference in Berlin on 19 and 20 February 2014.
Circulate is an annual conference for scientists, medical researchers, diagnostic and pharmaceutical companies pioneering the emerging field of circulating tumour cells (CTCs) and circulating cancer biomarkers.
At the conference, Mr Hari Nageswaran, a Clinical Research Fellow from the University of Surrey, will present initial data from a study entitled 'Use of a new size based CTC capture and harvest technology for colorectal cancer studies'. Mr Nageswaran used ANGLE's Parsortix system to carry out the study.
ANGLE's Parsortix system enables the capture of CTCs from cancer patient blood for mutational analysis. The Parsortix system uses a simple blood test to capture the cancer cells for analysis in contrast to the established solid tumour biopsy process where cells are surgically removed from the primary tumour. The Company's liquid biopsy has key medical advantages in that (i) being a simple blood test, it is non-invasive (ii) it can be used for inaccessible tumours where a solid biopsy is not possible or is very difficult and (iii) it can be repeated as often as required during the patient's treatment, which is important as the patient's cancer mutates over time.
Following ANGLE's successful deployment of the Parsortix system with key opinion leaders, and the Company's success in securing a CE Mark for the product, ANGLE is now making the Parsortix system available for sale to the European clinical market.
ANGLE's Founder and Chief Executive, Andrew Newland, commented:
"We believe that the ability of our patented Parsortix system to capture CTCs from patient blood opens a wide range of potential applications in treating cancer patients and we look forward to attending the Circulate conference and discussing that capability with key industry, medical and research players involved in personalised cancer care. We also look forward to Mr Nageswaran's presentation and his insight into the medical significance of the Parsortix system."
required field - 18 Feb 2014 08:52 - 141 of 195
Just repeating myself, but 200p plus could be on the cards...(with sales and contracts)...
skinny
- 24 Feb 2014 07:27
- 142 of 195
Use of Parsortix System with Liver Cancer Patients
USE OF PARSORTIX SYSTEM WITH METASTATIC LIVER CANCER PATIENTS
AND UPDATE FOLLOWING CIRCULATE CONFERENCE
ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce initial findings from a study using ANGLE's Parsortix system to analyse circulating tumour cells (CTCs) in metastatic liver cancer patients.
Mr Hari Nageswaran, a Clinical Research Fellow from the University of Surrey's Oncology Department, presented initial data from the study at the 4th Annual Circulate conference in Berlin. Circulate is an annual conference for scientists, medical researchers, diagnostic and pharmaceutical companies pioneering the emerging field of CTCs and circulating cancer biomarkers.
In the study, entitled 'Use of a new size based CTC capture and harvest technology for colorectal cancer studies', the Parsortix system was used to investigate the number of CTCs in the blood of colorectal cancer patients who, following surgery to remove the cancer from the colon and chemotherapy, had relapsed with secondary liver cancer. The study compares the CTC count in the peripheral and hepatic (liver) veins, from bloods taken during surgery to remove a section of the liver.
Even though these patients had undergone surgery to remove their primary tumour and had chemotherapy, the Parsortix system was still able to capture CTCs, from 2ml blood samples, in the peripheral blood of 65% of the patients and in the hepatic blood of 82% of the patients, a significantly higher proportion than might be expected with other systems.
The study revealed a higher concentration of CTCs found in the hepatic blood than the peripheral blood, indicating that CTC concentration in the blood is higher when in closer proximity to the location of the secondary cancer.
The study has now been extended to investigate the CTC concentration in the hepatic vein before and after surgery and the initial findings suggest that the concentration of CTCs is higher after surgery than before.
If further work confirms that this is the case, then it will be an important finding as it will indicate that the process of surgery itself may result in the release of CTCs into the bloodstream.
Further information on Mr Nageswaran's findings is available on ANGLE's website at: www.angleplc.com/partnering.asp
4th Annual Circulate conference
ANGLE showcased its Parsortix system at the Circulate conference. The Parsortix system is now available for sale for CTC research and, within Europe, for clinical use in patient care.
There was considerable interest in the Parsortix system from conference participants, primarily experts in the field of CTCs with a good understanding of emerging medical science in the field.
The Parsortix system was well received and the core competitive advantages of the system were recognised.
ANGLE's Founder and Chief Executive, Andrew Newland, commented:
"We are delighted that use of the Parsortix system by Mr Nageswaran as part of his clinical research may, if the initial data points are confirmed, lead to important medical findings for the benefit of liver cancer patients in the future.
"We are also pleased with the interest in the Parsortix system seen at the Circulate conference and enthusiastic about the potential for the adoption of the system as part of a new approach of personalised care in treating cancer patients over the coming years."
USE OF PARSORTIX SYSTEM WITH METASTATIC LIVER CANCER PATIENTS
AND UPDATE FOLLOWING CIRCULATE CONFERENCE
ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce initial findings from a study using ANGLE's Parsortix system to analyse circulating tumour cells (CTCs) in metastatic liver cancer patients.
Mr Hari Nageswaran, a Clinical Research Fellow from the University of Surrey's Oncology Department, presented initial data from the study at the 4th Annual Circulate conference in Berlin. Circulate is an annual conference for scientists, medical researchers, diagnostic and pharmaceutical companies pioneering the emerging field of CTCs and circulating cancer biomarkers.
In the study, entitled 'Use of a new size based CTC capture and harvest technology for colorectal cancer studies', the Parsortix system was used to investigate the number of CTCs in the blood of colorectal cancer patients who, following surgery to remove the cancer from the colon and chemotherapy, had relapsed with secondary liver cancer. The study compares the CTC count in the peripheral and hepatic (liver) veins, from bloods taken during surgery to remove a section of the liver.
Even though these patients had undergone surgery to remove their primary tumour and had chemotherapy, the Parsortix system was still able to capture CTCs, from 2ml blood samples, in the peripheral blood of 65% of the patients and in the hepatic blood of 82% of the patients, a significantly higher proportion than might be expected with other systems.
The study revealed a higher concentration of CTCs found in the hepatic blood than the peripheral blood, indicating that CTC concentration in the blood is higher when in closer proximity to the location of the secondary cancer.
The study has now been extended to investigate the CTC concentration in the hepatic vein before and after surgery and the initial findings suggest that the concentration of CTCs is higher after surgery than before.
If further work confirms that this is the case, then it will be an important finding as it will indicate that the process of surgery itself may result in the release of CTCs into the bloodstream.
Further information on Mr Nageswaran's findings is available on ANGLE's website at: www.angleplc.com/partnering.asp
4th Annual Circulate conference
ANGLE showcased its Parsortix system at the Circulate conference. The Parsortix system is now available for sale for CTC research and, within Europe, for clinical use in patient care.
There was considerable interest in the Parsortix system from conference participants, primarily experts in the field of CTCs with a good understanding of emerging medical science in the field.
The Parsortix system was well received and the core competitive advantages of the system were recognised.
ANGLE's Founder and Chief Executive, Andrew Newland, commented:
"We are delighted that use of the Parsortix system by Mr Nageswaran as part of his clinical research may, if the initial data points are confirmed, lead to important medical findings for the benefit of liver cancer patients in the future.
"We are also pleased with the interest in the Parsortix system seen at the Circulate conference and enthusiastic about the potential for the adoption of the system as part of a new approach of personalised care in treating cancer patients over the coming years."
required field - 03 Mar 2014 08:14 - 143 of 195
Blue today.....good progress here...
skinny
- 24 Mar 2014 14:16
- 144 of 195
required field - 24 Mar 2014 18:38 - 145 of 195
Looking good.....200p plus is my target....42 million market cap.....imagine if hospitals all over the world adopt their cancer cell trap system....
skinny
- 08 Apr 2014 07:54
- 146 of 195
required field - 08 Apr 2014 08:09 - 147 of 195
Yep...progressing nicely.....
skinny
- 23 May 2014 13:10
- 148 of 195
RF - do you still follow these - the up trend is well and truly broken.
required field - 23 May 2014 13:45 - 149 of 195
Yes...not too happy....expected a better performance from the sp...will stay put...perhaps some good news is on the way...
skinny
- 23 May 2014 14:35
- 150 of 195
They are on my wish list - it looks like things may become clearer later this year.
skinny
- 22 Jul 2014 07:11
- 151 of 195
required field - 28 Aug 2014 19:24 - 152 of 195
Upward trend here....nice....
Bullshare
- 11 Sep 2014 17:09
- 153 of 195
Learn from the expertsYou can now book your free tickets for our big event on Saturday 13 September in partnership with the London Stock Exchange. Held at the Business Design Centre in Islington, North London, The Stock Market Show is a full day event designed to help you understand investing. We have secured a large number of financial experts to explain in simple terms how you should go about investing in the stock market, the ways in which to research individual stocks and how to use different investment and trading accounts.
Tickets for the event are free but must be booked in advance you can also book your seminar sessions on our five separate stages.
The day is about to become a hot talking point among investors across the country as we are very pleased to announce This is Money as our media partner, a website read by millions of people and part of the Daily Mail & General Trust (DMGT) media stable.
• Hear from more than 50 speakers across 5 stages including: product experts, CEOs from listed companies and renowned journalists from Shares including Daniel Coatsworth, Mark Dunne, Steven Frazer and Tom Sieber who will all be giving presentations on investing.
• Speak with over 40 exhibitors from a range of AIM companies brokers and platform providers including: Alecto Minerals, Advanced Computer Software Group, Angle, Avation, Azonto Petroleum, Chaarat Gold, Corero Group Services, eg Solutions, EMIS, Fastnet Oil & Gas, Flowgroup, Fox Marble, Getech, Horizon Discovery, InternetQ, NetDimensions, Nostra Terra Oil & Gas, Premier African Minerals, Valirx, Velocys, Wishbone Gold and XL Media.
• Learn about investment topics tailored to suit a range of investors from novice to expert
• Meet with top financial services providers including; Aberdeen Asset Management, AJ Bell Youinvest, Amati Global Investors, Boost, CMC Markets, ETF Securities, Hargreaves Lansdown, IG, Killik & Co, KPMG, London Stock Exchange, Panmure Gordon, Reyker Securities,Société Générale, Stockopedia and ThisisMoney.
Why you should attend:
We have structured the entire programme around one core principal: financial education
Learn about:
• What you need to become a successful investor
• Managing your own pension using stocks and shares
• The simple approach to valuing companies
• The importance of risk when researching stocks
• The most important areas in company documents and financial accounts
• Reading chart patterns
• An introduction to exchange traded funds and bonds
• Plus a host of other topics on industry sectors, trading techniques, market mechanics and tax issues
Hear from:
• Shares journalists
• Financial services professionals
• Chief executives of quoted companies
• Leading market commentators
Your chance to meet:
• Share dealing and pension providers
• Quoted companies
• Shares journalists
• Representatives from the London Stock Exchange
• Fellow investors
For more information and to register go to: http://www.thestockmarketshow.com/
required field - 25 Sep 2014 21:12 - 154 of 195
Could rocket if this becomes some sort of universal standard for cancer cell capture worldwide !.......profits could be staggering !....
skinny
- 27 Jan 2015 07:16
- 155 of 195
required field - 27 Jan 2015 15:41 - 156 of 195
Well...at least this one looks promising....
skinny
- 27 Jan 2015 15:43
- 157 of 195
kimoldfield
- 27 Jan 2015 16:02
- 158 of 195
Well I don't know about that skinny, but I do know I need a stiff drink after selling too soon! :o)
required field - 27 Jan 2015 16:03 - 159 of 195
Not sure about viagra....but as my sharepicking has been hopeless lately.....anyway ; this looks to have fantastic potential !....now I've said that : watch it dive...
kimoldfield
- 27 Jan 2015 16:57
- 160 of 195
Could be a longish haul but for a long term punt it has loads of potential. I was waiting for the sp to pull back a bit before buying back in. I must rename myself as stupidboypike!
mitzy - 27 Jan 2015 19:26 - 161 of 195
200p plus could be on the cards here.
skinny
- 28 Jan 2015 06:57
- 162 of 195
required field - 28 Jan 2015 09:17 - 163 of 195
I'm in but I think there has been a mix-up and that this company is in fact Afren......mistakes can happen...
skinny
- 29 Jan 2015 07:19
- 164 of 195
Interim Results for the six months ended 31 October 2014
MOVING CLOSER TO A CLINICAL APPLICATION
ANGLE plc (AIM: AGL and OTCQX: ANPCY), the specialist medtech company, today announces unaudited interim results for the six months ended 31 October 2014.
Highlights
· Collaboration agreements signed with a further five leading international cancer research centres bringing the total number of key opinion leaders working with the Parsortix system to eight covering the UK, Europe and the United States collectively covering breast, colorectal, oesophageal, ovarian, prostate and pancreatic cancers
· Four of the key opinion leaders publicly reported during the period bringing a total of five key opinion leaders reporting positively on their evaluation of the Parsortix system. The remaining three are in progress
· Continued progress towards FDA authorisation
· Second US patent granted relating to improvements in technology and specific use for foetal and cancer applications
· Management team strengthened with US specialist medtech commercialisation experience
· Loss for the half year of £1.6 million (H1 2014: loss £0.5 million) reflecting planned investment in Parsortix of £1.6 million (H1 2014: £1.1 million)
· Cash balance at 31 October 2014 of £2.3 million (30 April 2014: £3.9 million)
Progress post the half year end
· Commercial collaboration established with the diagnostics division of a large pharmaceutical company to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform as a front end to the Collaborator's single cell analysis system
· Commercial collaboration established with EKF Diagnostics Holdings plc to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with EKF's PointMan™ DNA enrichment technology as a liquid biopsy to provide a combined solution
· Patient study provides basis for clinical application in ovarian cancer with the Medical University of Vienna reporting the Parsortix system delivers "unprecedented sensitivity and specificity". Following these excellent results in ovarian cancer, ANGLE has commenced a process, in collaboration with the Medical University of Vienna to develop a clinical application for ovarian cancer.
MOVING CLOSER TO A CLINICAL APPLICATION
ANGLE plc (AIM: AGL and OTCQX: ANPCY), the specialist medtech company, today announces unaudited interim results for the six months ended 31 October 2014.
Highlights
· Collaboration agreements signed with a further five leading international cancer research centres bringing the total number of key opinion leaders working with the Parsortix system to eight covering the UK, Europe and the United States collectively covering breast, colorectal, oesophageal, ovarian, prostate and pancreatic cancers
· Four of the key opinion leaders publicly reported during the period bringing a total of five key opinion leaders reporting positively on their evaluation of the Parsortix system. The remaining three are in progress
· Continued progress towards FDA authorisation
· Second US patent granted relating to improvements in technology and specific use for foetal and cancer applications
· Management team strengthened with US specialist medtech commercialisation experience
· Loss for the half year of £1.6 million (H1 2014: loss £0.5 million) reflecting planned investment in Parsortix of £1.6 million (H1 2014: £1.1 million)
· Cash balance at 31 October 2014 of £2.3 million (30 April 2014: £3.9 million)
Progress post the half year end
· Commercial collaboration established with the diagnostics division of a large pharmaceutical company to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform as a front end to the Collaborator's single cell analysis system
· Commercial collaboration established with EKF Diagnostics Holdings plc to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with EKF's PointMan™ DNA enrichment technology as a liquid biopsy to provide a combined solution
· Patient study provides basis for clinical application in ovarian cancer with the Medical University of Vienna reporting the Parsortix system delivers "unprecedented sensitivity and specificity". Following these excellent results in ovarian cancer, ANGLE has commenced a process, in collaboration with the Medical University of Vienna to develop a clinical application for ovarian cancer.
required field - 09 Feb 2015 10:08 - 165 of 195
This is looking quite good......Been stocking up with this one.....I've been wrong many a time but....I can imagine a 400p tag on this .....it's just that the sales potential is simply enormous !.....cancer is terrible and this company can trap the bad cells....incredible ...just like a filter....this reminds me of Gulf keystone before the Shaikan oil discovery....in what could be achieved...just wait until a big pharmaceutical company comes along with a mouthwatering offer of some kind....woooossshhh....
required field - 23 Feb 2015 09:56 - 166 of 195
Recovering well.....well financed with tremendous potential....one to watch....
Bullshare
- 20 Mar 2015 16:36
- 167 of 195
Shares Investor Evenings is going to Manchester, we will showcase four leading companies bringing them together in one room for one evening only.
Directors present their latest plans regarding development and growthAn opportunity to talk directly to the companies and personally put forward your questionsThe chance to network with other attendees over drinks and canapés - private investors, wealth managers, private client brokers, fund managers and financial institutionsThe evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.
Date:Tuesday 31st March 2015
Venue:Lancashire County Cricket Club, Manchester, Emirates Old Trafford, Talbot Road, Manchester, M16 0PX
Event Timings:| 18.00 | Registration and coffee | |
| 18.30 | Presentations • Neil O'Brien, CEO - Alkane Energy (ALK:AIM) • Andrew Newland, CEO - Angle (AGL:AIM) • Dr Satu Vainikka, Chief Executive Officer - Valirx (VAL:AIM) • Martin Perrin, Chief Financial Officer - Vipera (VIP:AIM) | |
| 20.30 | Drinks reception and canapés | |
| 21.30 | Close |
Attendance is free, but spaces are limited. Register now to secure your place!
Alkane Energy (ALK:AIM)
 | Alkane Energy is one of the UK’s fastest growing independent power generators. The Company operates mid-sized 'gas to power' electricity plants providing both predictable and fast response capacity to the grid. Alkane now has a total of 140MW of installed generating capacity and an electricity grid capacity of 160MW. |
Angle (AGL:AIM)
 | ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L). ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. In December 2013, ANGLE secured CE Mark regulatory authorisation for the clinical market in 2013 and FDA approval is planned for 2014. The primary application is the capture of circulating tumour cells (CTCs) in patient blood for: • Early detection of cancer;• Personalised cancer treatment;• Monitoring of cancer patients during treatment; and• Post-treatment monitoring of cancer patients in remission. |
Valirx (VAL:AIM)
 | Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation. |
Vipera (VIP:AIM)
 | Vipera is a leading provider of mobile financial services platforms. The Vipera platform provides the easiest, fastest, most cost-effective way to develop and operate mobile data services. Solutions powered by Vipera run today on more than 500,000 phones, on hundreds of mobile networks in many countries. Founded in 2005, Vipera has offices in Zurich, Milan and London. |
required field - 25 Mar 2015 09:24 - 168 of 195
Sp starting to perform now that the fund raising at 65p is almost out of the way...4 times oversubscribed...
required field - 21 Apr 2015 09:00 - 169 of 195
Great update...if they could turn this into commercial orders the sp would fly.....
required field - 24 Apr 2015 13:00 - 170 of 195
Much more to come here.....just wait till commercial orders.....
required field - 29 Apr 2015 11:25 - 171 of 195
Sp rising nicely.......commercial orders coming ?........or a portable home diy kit ?.....
required field - 30 Apr 2015 10:33 - 172 of 195
Up again......a hospital commercial contract would help.....
skinny
- 11 May 2015 15:24
- 173 of 195
Above a quid.
;MA(50);MA(200)&IND=MACD(26,12,9);RSI(14);VOLMA(60)&Layout=2Line;Default;Price;HisDate&XCycle=&XFormat=)
Bullshare
- 25 Nov 2015 14:10
- 174 of 195
Shares Investor Evenings showcase up to four presentations from leading companies bringing them together in one room for one evening only.
Directors present their latest plans regarding development and growthAn opportunity to talk directly to the companies and personally put forward your questionsThe chance to network with other attendees over drinks and canapés - private investors, wealth managers, private client brokers, fund managers and financial institutionsThe evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.
Tuesday 15th December 2015
Venue:Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR
Event Timings:| 18.00 | Registration and coffee | |
| 18.30 | Presentations • Andrew Newland, CEO - Angle (AGL) • Jog Dhody, CFO - Regenersis (RGS) • Dr. Satu Vainikka, CEO - Valirx (VAL) + More to be announced | |
| 20.30 | Drinks reception and canapés | |
| 21.30 | Close |
Attendance is free, but spaces are limited. Register now to secure your place!
Angle (AGL)
 | ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L).
ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress.
The primary application is the capture of circulating tumour cells (CTCs) in patient blood for: · Early detection of cancer; · Personalised cancer treatment; · Monitoring of cancer patients during treatment; and · Post-treatment monitoring of cancer patients in remission. |
Regenersis (RGS)
 | Regenersis is a leading, strategic outsourcing partner to the world’s premier consumer technology brands. Regenersis has built an increasingly global network of repair centres, delivered double digit revenue and profit growth, through cross-sell related services to major OEMs and network operators. In addition, the Group has traction with its scalable, high margin Advanced Solutions offering across the mobile and set top box markets. |
Valirx (VAL)
 | Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation. |
Bullshare
- 18 Dec 2015 09:06
- 175 of 195
MEET THE TECH SUPERSTARS OF TOMORROW
A 12-month share price performance of the companies that presented at the Innovators & Investors Forum last year included:
Elecosoft +42%
Idox +22%
Instem +34%
KBC Advanced +45%
XL Media +41%
The Innovators & Investors Forum, organised in partnership with Cenkos Securities and SHARES, is in its 4th year and is the UK's only technology investment show.
REGISTER NOW
Thousands of investors have attended our previous shows, attendees will also benefit from:Learning from industry experts and influencers about the markets, the technology sector and individual companies
Find out from fund managers how they view the future in 2016
Meet the directors of up to 30 listed technology focused companies
Listen to our expert team of SHARES journalists
The event is supported with an extensive conference program
Keynote Speakers:
Daniel Coatsworth, Editor - Shares
Mark Dunne, Growth Companies Reporter - SHARES
Steven Frazer, Online Editor - SHARES
Russ Mould, Investment Director - AJ Bell
Richard Penny, Senior Fund Manager - Legal & General UK Alpha Trust
Simon Strong, Head of Research, Growth Companies - Cenkos Securities
Further speakers to be announced soon.
Meet the teams and talk directly to CEOs and Directors from:
Advanced Oncotherapy
ANGLE
CML Microsystems
Cyan Technology
Eckoh
eg solutions
Ilika
Instem
Lombard Risk
Mirada
Plastics Capital
SHARES
TyraTech
Further companies to be announced soon.
Date: 2nd February 2016
Venue: Business Design Centre, London
Event timings
Registration: from 09:00
Conference: 09:45 - 17:00
Exhibition: 09:00 - 18:00
REGISTER NOW
Bullshare
- 04 Feb 2016 11:15
- 176 of 195
Andrew Newland interviewed by Shares in the first of our Spotlight series
http://www.sharesmagazine.co.uk/videos/?vid=65566
http://www.sharesmagazine.co.uk/videos/?vid=65566
kimoldfield
- 18 Apr 2016 12:20
- 177 of 195
ANGLE, the specialist medtech company, says results of the University of Southern California (USC) Norris Comprehensive Cancer Centre's ongoing work with ANGLE's Parsortix system have demonstrated the potential for the use of Parsortix as a liquid biopsy for metastatic breast cancer.
USC head to head patient data will be presented today at AACR 2016 (the American Association for Cancer Research Annual Meeting 2016), which demonstrates a statistically significant correlation in metastatic breast cancer between analysis of CTCs (circulating tumor cells) harvested from a simple blood test using Parsortix with similar analysis of tissue obtained from invasive biopsy of a secondary cancer site.
The Directors believe that the data demonstrates the potential for the Parsortix liquid biopsy (simple blood test) to replace the invasive biopsy.
Well, the market isn't impressed by much these days! Bought some to stick in the drawer until who knows when!
USC head to head patient data will be presented today at AACR 2016 (the American Association for Cancer Research Annual Meeting 2016), which demonstrates a statistically significant correlation in metastatic breast cancer between analysis of CTCs (circulating tumor cells) harvested from a simple blood test using Parsortix with similar analysis of tissue obtained from invasive biopsy of a secondary cancer site.
The Directors believe that the data demonstrates the potential for the Parsortix liquid biopsy (simple blood test) to replace the invasive biopsy.
Well, the market isn't impressed by much these days! Bought some to stick in the drawer until who knows when!
Bullshare
- 06 Jan 2017 15:52
- 178 of 195
Growth & Innovation Forum 2017
Tuesday 31st January 2017
MEET YOUR NEXT GROWTH COMPANY INVESTMENT
Click here to REGISTER now
Share price performance of some of the companies that attended the last event include:
Cyan +43%
Instem + 44%
Satellite Solutions Worldwide +79%
Summit Therapeutics +32%
XLMedia +46%
The Growth and Innovation Forum, organised in partnership with Cenkos Securities and Shares, is in its 5th year and is the UK's only growth and technology company investment show.
Thousands of investors have attended our previous shows. This year attendees will be able to:
· Learn from industry experts and influencers about the markets, the technology sector and individual companies
· Find out from fund managers how they view the future in 2017 and beyond
· Meet the directors of up to 40 listed growth companies
· Listen to presentations from our expert team of Shares journalists
Key note Speakers at the Show include:
Daniel Coatsworth, Editor - Shares
Russ Mould, Investment Director - AJ Bell
Richard Penny, Senior Fund Manager - Legal & General UK Alpha Trust
Simon Strong, Head of Research, Growth Companies - Cenkos Securities
Further keynote speakers to be announced.
Presenting at the Show and available to meet during the day will be a number of listed company CEOs and Directors:
Andrew Newland, CEO - ANGLE
Alastair Smith, CEO - Avacta
Rachel Elias-Jones, CFO - Bango
Keith Butcher, CFO - Blancco Technology Group
Terry Hart, CFO - CityFibre
Simon Cleaver, CEO - CloudCall
Jamal Rushdy, CEO - Collagen Solutions
John Cronin, Executive Chairman - CyanConnode
Philipp Prince, CFO - Defenx
Frontier IP Group
Phil Reason, CEO - Instem
Steve Flavell, co-CEO - LoopUp
Jose Luis Vazquez, CEO - Mirada
Ian Smith, CEO - One pm Finance
Plastics Capital
Mark Braund, CEO - RedstoneConnect
Simon Kings, Executive Director - TP Group
David Richards, Interim Chairman, President, CEO & Co-founder - WANdisco
More companies to be announced.
For more information go to the event website here
Tuesday 31st January 2017
MEET YOUR NEXT GROWTH COMPANY INVESTMENT
Click here to REGISTER nowShare price performance of some of the companies that attended the last event include:
Cyan +43%
Instem + 44%
Satellite Solutions Worldwide +79%
Summit Therapeutics +32%
XLMedia +46%
The Growth and Innovation Forum, organised in partnership with Cenkos Securities and Shares, is in its 5th year and is the UK's only growth and technology company investment show.
Thousands of investors have attended our previous shows. This year attendees will be able to:
· Learn from industry experts and influencers about the markets, the technology sector and individual companies
· Find out from fund managers how they view the future in 2017 and beyond
· Meet the directors of up to 40 listed growth companies
· Listen to presentations from our expert team of Shares journalists
Key note Speakers at the Show include:
Daniel Coatsworth, Editor - Shares
Russ Mould, Investment Director - AJ Bell
Richard Penny, Senior Fund Manager - Legal & General UK Alpha Trust
Simon Strong, Head of Research, Growth Companies - Cenkos Securities
Further keynote speakers to be announced.
Presenting at the Show and available to meet during the day will be a number of listed company CEOs and Directors:
Andrew Newland, CEO - ANGLE
Alastair Smith, CEO - Avacta
Rachel Elias-Jones, CFO - Bango
Keith Butcher, CFO - Blancco Technology Group
Terry Hart, CFO - CityFibre
Simon Cleaver, CEO - CloudCall
Jamal Rushdy, CEO - Collagen Solutions
John Cronin, Executive Chairman - CyanConnode
Philipp Prince, CFO - Defenx
Frontier IP Group
Phil Reason, CEO - Instem
Steve Flavell, co-CEO - LoopUp
Jose Luis Vazquez, CEO - Mirada
Ian Smith, CEO - One pm Finance
Plastics Capital
Mark Braund, CEO - RedstoneConnect
Simon Kings, Executive Director - TP Group
David Richards, Interim Chairman, President, CEO & Co-founder - WANdisco
More companies to be announced.
For more information go to the event website here
required field - 21 Jun 2017 12:59 - 179 of 195
Better days ahead perhaps for this company ?....if commercialisation is coming then the sp would rise sharply....fingers crossed....
required field - 04 Jul 2017 16:22 - 180 of 195
Very surprised how little attention this company is attracting...and yet...this could be a major success this year....
hangon - 18 Jul 2017 15:28 - 181 of 195
I am suspicious of businesses ( Esp in AIM ) that can't explain what they do in a few simple words.... Read their profile in MoneyAM to read waffle.....
This is a Cell-based Bio-company - but excuse me if that's wrong, for my head is still spinning after reading any of their notices.
For that reason alone, other folks may invest where the Business is clearly described. (( It shows a clarity of Mind-Set, IMHO )).
+ Investment is about TRUST . . . in very small measure, as some/many/all other companies promise £ots and deliver Zippo.
I'm not convinced that farming bad-cells is exactly profitable - we've got plenty of struggling Bio-Co's who are just on the brink..... of collapse IMHO, although no-one wishes for that. In the UK there is little demand for out-of-the-box thinkers . . . . that's why Parliament spends huge amounts on HS2 while clawing back pennies for tower-block safety issues . . . I'll get my coat.
This is a Cell-based Bio-company - but excuse me if that's wrong, for my head is still spinning after reading any of their notices.
For that reason alone, other folks may invest where the Business is clearly described. (( It shows a clarity of Mind-Set, IMHO )).
+ Investment is about TRUST . . . in very small measure, as some/many/all other companies promise £ots and deliver Zippo.
I'm not convinced that farming bad-cells is exactly profitable - we've got plenty of struggling Bio-Co's who are just on the brink..... of collapse IMHO, although no-one wishes for that. In the UK there is little demand for out-of-the-box thinkers . . . . that's why Parliament spends huge amounts on HS2 while clawing back pennies for tower-block safety issues . . . I'll get my coat.
Bullshare
- 26 Oct 2017 14:31
- 182 of 195
Looking for new investment opportunities? Come to the Sharesand AJ Bell evening event to find out more about Angle, Royal Road Minerals, ThinCats and Touchstone Exploration.
If you are looking for new investment opportunities there is no better starting point than coming along to our Shares Spotlight evening event on 28 November 2017. You will have the chance to meet the directors of four fast growing companies and find out about their plans for the rest of 2017 and what is in store for 2018.
During the event and afterwards over drinks, investors will have the chance to listen to presentations from each of the companies and talk directly to the company directors about their plans and vision for their businesses.
ANGLE (AGL) - ANGLE plc is a commercially driven medical diagnostic company specializing in the development of pioneering products in the fields of cancer diagnostics and fetal health. Their lead product is the Parsortix cell separation system, which can capture very rare cells from blood. This includes circulating tumor cells (CTCs) in cancer patient blood – even when there is a ratio of less than one CTC for every one billion healthy cells. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient’s cancer in order to more knowledgeably personalize their care.
Royal Road Minerals - Royal Road Minerals is a gold and copper focused exploration and development company. The Company’s objective is to advance the exploration and development of its projects in Colombia and Nicaragua and to discover new assets in Colombia and Nicaragua. The Company’s priority is the discovery and acquisition of high-grade, high-margin copper and gold projects in highly prospective regions and in sustainable and inclusive arrangements with local joint venture partners. Royal Road Minerals has a strong social and environmental conscience and aims to exemplify world’s best practice in regards to all aspects of gold exploration and development.
ThinCats - Thincats are one of the pioneers of the peer-to-peer business lending industry; specialising in loans with security and linking retail and institutional investors directly with established business borrowers to provide a serious alternative to high street banks. The company was founded in the aftermath of the global financial crisis, with the aim of offering loans to UK businesses struggling to access funding through traditional channels, whilst providing investors with attractive rates of interest unavailable through many conventional investment portfolios.
Touchstone Exploration (TXP) - Touchstone Exploration Inc. is a UK listed but Canadian-based, international upstream oil and gas company currently active in the Republic of Trinidad and Tobago. It is one of the largest independent onshore oil producers in Trinidad, with an experienced management and executive team that have a track record of delivering value to shareholders. In Trinidad, the Company’s interests in approximately 90,000 gross acres of exploration and development rights make it one of the largest independent onshore oil producers in Trinidad. Touchstone holds over 8,700 working interest acres of onshore producing properties that have known crude oil reserves as well as over 55,000 exploration and undeveloped working interest acres that are being evaluated.
Places at this event are very limited, so register now for your free ticket.
The evening is a perfect opportunity for existing shareholders or potential investors to hear from those that matter, the directors running the companies and fund managers managing their fund. Who better to explain the future potential and strategy.
Tuesday 28 November 2017
Venue:Novotel Tower Bridge, London EC3N 2NR, 10 Pepys Street, London, EC3N 2NR
Event Timings:| 18.00 | Registration and coffee | |
| 18.30 | Presentations • Andrew Newland, Chief Executive - ANGLE • Tim Coughlin, CEO - Royal Road Minerals • John Mould, CEO - ThinCats • Paul Baay, CEO - Touchstone Exploration | |
| 20.30 | Drinks reception and canapés | |
| 21.30 | Close |
AJ Bell Youinvest
 | AJ Bell Youinvest is a multi-award winning provider of SIPPs, stocks and shares ISAs, Junior ISAs, Junior SIPPs and share dealing accounts. We offer customers access to a market leading range of investment options, including: shares, funds, ETFs, investment trusts and much more. Our online dealing service starts from just £4.95 and never costs more than £9.95 per deal.
|
ANGLE
 | ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L). ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress. The primary application is the capture of circulating tumour cells (CTCs) in patient blood for: · Early detection of cancer; · Personalised cancer treatment; · Monitoring of cancer patients during treatment; and · Post-treatment monitoring of cancer patients in remission. |
Royal Road Minerals
 | Royal Road Minerals is a gold and copper focused exploration and development company. The Company’s objective is to advance the exploration and development of its projects in Colombia and Nicaragua and to discover new assets in Colombia and Nicaragua. The Company’s priority is the discovery and acquisition of high-grade, high-margin copper and gold projects in highly prospective regions and in sustainable and inclusive arrangements with local joint venture partners. Royal Road Minerals has a strong social and environmental conscience and aims to exemplify world’s best practice in regards to all aspects of gold exploration and development. |
ThinCats
 | ThinCats are one of the pioneers of the peer-to-peer business lending industry; specialising in loans with security and linking retail and institutional investors directly with established business borrowers to provide a serious alternative to high street banks. The company was founded in the aftermath of the global financial crisis, with the aim of offering loans to UK businesses struggling to access funding through traditional channels, whilst providing investors with attractive rates of interest unavailable through many conventional investment portfolios. A key element of the ThinCats’ ethos has always been to avoid the algorithm-led decision making often used by banks; the founders were keen to hear the stories behind the borrowers’ investment needs, and assess each one based on its merits. The company continues to work in this way, harnessing the knowledge of financial experts to assess each loan application, thereby encouraging growth, development and innovation in UK business. |
Touchstone Exploration
 | Touchstone Exploration Inc. is a UK listed but Canadian-based, international upstream oil and gas company currently active in the Republic of Trinidad and Tobago. It is one of the largest independent onshore oil producers in Trinidad, with an experienced management and executive team that have a track record of delivering value to shareholders. In Trinidad, the Company’s interests in approximately 90,000 gross acres of exploration and development rights make it one of the largest independent onshore oil producers in Trinidad. Touchstone holds over 8,700 working interest acres of onshore producing properties that have known crude oil reserves as well as over 55,000 exploration and undeveloped working interest acres that are being evaluated. |
Bullshare
- 25 Jan 2018 14:25
- 183 of 195
The Sharesand AJ Bell Mediaevening event in Manchester is an opportunity for senior board directors from fast growing listed PLCs to make a presentation about their company and update existing & potential investors on their business plans for 2018.
During the event and afterwards over drinks, investors will have the chance to discover new investment opportunities and get to know the companies better by talking one on one with the company directors.
All attendees will be entered into free prize draws for:
Two pairs of tickets for Sale Sharks v Wasps on Sat 7th April at the AJ Bell Stadium, Eccles, Manchester M30 7WH http://www.salesharks.com
Champagne afternoon tea for TWO at Cloud 23 on the 23rd floor of the legendary Beetham Tower in Deansgate, Manchester. https://www.cloud23bar.com/
Evening Tasting Gift Experience at the Manchester Wine School. A gift voucher for TWO places on one of their evening tastings in Manchester City Centre. Gin, Champagne & Sparkling, Cheese or Food and Wine tasting/special event course of your choice. http://www.manchesterwineschool.com
The event will take place close to the City Centre at the Macdonald Manchester Hotel (London Road, Manchester M1 2PG) which is easily accessible by road, tram and rail.
Companies presenting:
ANGLE (AGL) - ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market. ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress.
The primary application is the capture of circulating tumour cells (CTCs) in patient blood for; Early detection of cancer; Personalised cancer treatment; Monitoring of cancer patients during treatment; and Post-treatment monitoring of cancer patients in remission.
Cadence Minerals (KDNC) - Cadence is dedicated to smart investments for a greener world. The planet needs rechargeable batteries on a global scale – upcoming supersized passenger vehicles, lorries and buses – require lithium and other technology minerals to power their cells. Cadence is helping find these minerals in new places and extracting them in new ways, which will meet the demand of this burgeoning market. With over £35 million vested in key assets globally, Cadence is helping us reach tomorrow, today.
First Sentinel - First Sentinel is a consortium of companies focused on alternative investments, specializing in equity and debt deals with appealing IRRs, as well as traditional Corporate Finance and Legal Services.
This consortium enables us to support our clients end to end, whether it be the individual investor or corporate offering.
First Sentinel PLC (NEX: FSEN) is an alternative investment company that provides growth capital for public and private company investments.
Plutus PowerGen(PPG) - Plutus PowerGen is a profitable AIM listed company that is constructing flexible generation and gas powered projects in the UK. It has identified multiple revenue streams and each site is relatively low cost to deliver.
Plutus PowerGen has has six operating projects across the UK with a further 400MW of sites under development. Since the introduction of intermittent, renewable power to the UK’s power generation mix, the National Grid is facing increasing instability and risk of brownouts and blackouts. Therefore a reliable source of power is required during periods of peak electricity demand and Plutus PowerGen’s projects can be turned on rapidly and remotely to address this requirement. Importantly, the Company has received an offer from a leading ‘Big Six’ multinational utility company to fund up to 20% of any 20MW renewable fuel or gas powered flexible energy projects going forward.
PrimaryBid - PrimaryBid the leading online equity funding platform, available on both web and mobile, that enables investors to gain access to placings, fundraisings and IPOs of AIM-listed companies. The platform is open to all investors and is supported by the broking community as a way of accessing, on behalf of their AIM clients seeking capital, the large and active private investor market, as well as institutions. To date almost £37m has been sourced for issuers, via the platform.
SkinBioTherapeutics (SBTX) - SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.
The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.
SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.
The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.
Tuesday 20 February 2018
Venue:Macdonald Manchester Hotel, London Road, Manchester, M1 2PG
Event Timings:| 17.45 | Registration and coffee | |
| 18.15 | Presentations • Andrew Newland, Chief Executive - ANGLE • Kiran Morzaria, Director & CEO - Cadence Minerals (KDNC) • Brian Stockbridge, CEO - First Sentinel • Charles Tatnall, Executive Chairman - Plutus PowerGen • Dave Mutton, COO - PrimaryBid • Cath O'Neill, CEO - SkinBioTherapeutics | |
| 20.30 | Drinks reception and canapés | |
| 21.30 | Close |
AJ Bell Youinvest
 | AJ Bell Youinvest is a multi-award winning provider of SIPPs, stocks and shares ISAs, Lifetime ISAs, Junior ISAs, Junior SIPPs and share dealing accounts. We offer customers access to a market leading range of investment options, including: shares, funds, ETFs, investment trusts and much more. Our online dealing service starts from just £1.50 and never costs more than £9.95 per online deal.
|
PrimaryBid
 | PrimaryBid is a leading FinTech business enabling investors to gain access to fundraisings of companies listed on UK Stock Exchanges. Our unique solution connects the large and active pool of private investors, with companies seeking to raise capital by issuing new shares. Traditionally, fundraises for listed companies have only been accessible by Institutions and a small number of high net worth investors, PrimaryBid allows all investors to have access to these fundraises at the same time and the same price, delivering open access regardless of the size of their investment. To date over £52m has been sourced via the platform. |
ANGLE
| ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L). ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress. The primary application is the capture of circulating tumour cells (CTCs) in patient blood for: · Early detection of cancer; · Personalised cancer treatment; · Monitoring of cancer patients during treatment; and · Post-treatment monitoring of cancer patients in remission. |
Cadence Minerals (KDNC)
 | Cadence is dedicated to smart investments for a greener world. The planet needs rechargeable batteries on a global scale – upcoming supersized passenger vehicles, lorries and buses – require lithium and other technology minerals to power their cells. Cadence is helping find these minerals in new places and extracting them in new ways, which will meet the demand of this burgeoning market. With over £35 million vested in key assets globally, Cadence is helping us reach tomorrow, today. |
First Sentinel
 | First Sentinel is a consortium of companies focused on alternative investments, specializing in equity and debt deals with appealing IRRs, as well as traditional Corporate Finance and Legal Services. This consortium enables us to support our clients end to end, whether it be the individual investor or corporate offering. First Sentinel PLC (NEX: FSEN) is an alternative investment company that provides growth capital for public and private company investments. (NEX: FSEN).
|
Plutus PowerGen
 | Plutus PowerGen is a profitable AIM listed company that is constructing flexible generation and gas powered projects in the UK. It has identified multiple revenue streams and each site is relatively low cost to deliver. Plutus PowerGen has six operating projects across the UK with a further 400MW of sites under development. Since the introduction of intermittent, renewable power to the UK’s power generation mix, the National Grid is facing increasing instability and risk of brownouts and blackouts. Therefore a reliable source of power is required during periods of peak electricity demand and Plutus PowerGen’s projects can be turned on rapidly and remotely to address this requirement. Importantly, the Company has received an offer from a leading ‘Big Six’ multinational utility company to fund up to 20% of any 20MW renewable fuel or gas powered flexible energy projects going forward. |
SkinBioTherapeutics
 | SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester. The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load. SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept. |
HARRYCAT
- 31 Jan 2018 10:09
- 184 of 195
StockMarketWire.com
Angle plc, a world-leading liquid biopsy company, reported revenues of £0.2m for the six months ended 31 October 2017 but losses from continuing operations widened to £3.4m.
The company noted several important operational highlights for the period including clinical evidence from successful US and European ovarian cancer studies in 400 patients.
While the acquisition of Axela for £3.6 million was said to have expanded the company's liquid biopsy capabilities. Extensive work toward FDA Class II clearance in metastatic breast cancer was completed.
Angle grew its installed base to over 145 Parsortix instruments worldwide (H1 2017: 120) with over 39,000 blood separations completed (H1 2017: 22,000).
Garth Selvey, Chairman, said:
"Angle has continued to make excellent progress in executing its strategy for commercialisation of the Parsortix system, and its adoption as a gold standard in liquid biopsy, during the first half of the year.'
'We have successfully completed two large scale ovarian cancer clinical studies, progressed our FDA studies, broadened our liquid biopsy capabilities to include a downstream analysis platform with the acquisition of assets of Axela, and secured corporate partnerships with two leading, global healthcare companies.'
'Our pivotal US FDA analytical and clinical studies in metastatic breast cancer are expected to complete in H2 CY 2018.'
'Angle is seeking to become the first company to receive FDA clearance for a product for harvesting intact circulating cancer cells from patient blood for subsequent analysis.'
'We believe this will differentiate ANGLE in the liquid biopsy market and will have a major positive impact, driving the business forward on numerous fronts.'
Angle plc, a world-leading liquid biopsy company, reported revenues of £0.2m for the six months ended 31 October 2017 but losses from continuing operations widened to £3.4m.
The company noted several important operational highlights for the period including clinical evidence from successful US and European ovarian cancer studies in 400 patients.
While the acquisition of Axela for £3.6 million was said to have expanded the company's liquid biopsy capabilities. Extensive work toward FDA Class II clearance in metastatic breast cancer was completed.
Angle grew its installed base to over 145 Parsortix instruments worldwide (H1 2017: 120) with over 39,000 blood separations completed (H1 2017: 22,000).
Garth Selvey, Chairman, said:
"Angle has continued to make excellent progress in executing its strategy for commercialisation of the Parsortix system, and its adoption as a gold standard in liquid biopsy, during the first half of the year.'
'We have successfully completed two large scale ovarian cancer clinical studies, progressed our FDA studies, broadened our liquid biopsy capabilities to include a downstream analysis platform with the acquisition of assets of Axela, and secured corporate partnerships with two leading, global healthcare companies.'
'Our pivotal US FDA analytical and clinical studies in metastatic breast cancer are expected to complete in H2 CY 2018.'
'Angle is seeking to become the first company to receive FDA clearance for a product for harvesting intact circulating cancer cells from patient blood for subsequent analysis.'
'We believe this will differentiate ANGLE in the liquid biopsy market and will have a major positive impact, driving the business forward on numerous fronts.'
required field - 11 Jan 2019 08:17 - 185 of 195
Important news from this company......if this is correct : could be a game changer.....
skinny
- 11 Jan 2019 08:20
- 186 of 195
Yes - off of yesterday's highs atm, but potentially a fantastic break through.
required field - 11 Jan 2019 08:30 - 187 of 195
Most people won't have yet spotted the what seems great news about the breakthrough in defeating cancer....if this is correct ; it is remarkable !.....
required field - 11 Jan 2019 08:41 - 188 of 195
Surprised that the sp is not much..much...higher...why are people selling this with incredible news....???
skinny
- 11 Jan 2019 09:01
- 189 of 195
It had a massive rise yesterday on the news!
required field - 11 Jan 2019 09:21 - 190 of 195
For about 5mn......strange time to realease an rns….some companies do that ….problem is the general public can miss the rns……..anyway...we shall see : one to watch now.....
Fred1new
- 11 Jan 2019 09:35
- 191 of 195
RF,
Advancement appears to be in "diagnosis" or "recognising" variants of "ovarian cancer".
That may improve subsequent "treatments" of such, but the technique is not the "cure" but could be a first stage towards one.
(Could be wrong in my interpretation.)
Advancement appears to be in "diagnosis" or "recognising" variants of "ovarian cancer".
That may improve subsequent "treatments" of such, but the technique is not the "cure" but could be a first stage towards one.
(Could be wrong in my interpretation.)
required field - 11 Jan 2019 10:35 - 192 of 195
Fred :.....it looks like a cure....99%...in mice...and now testing humans....in Switzerland trials....a system like this gets commercialised and the sky is the limit for this company......the big boys would want to buy this firm then.....
skinny
- 11 Jan 2019 11:36
- 193 of 195
Link copied :- Biotech minnow Angle triumphs with cancer blood testing kit
required field - 29 Jan 2019 10:56 - 194 of 195
More good news....could be a real winner this year, this company....
Dil
- 29 Jan 2019 14:12
- 195 of 195
Had a few last week.
Looks promising.
£1 by xmas :-)
Looks promising.
£1 by xmas :-)
| About MoneyAM | Ts and Cs | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us | Site Map | © 2025 MoneyAM |
Register now for FREE
Share Prices,
Stock Quotes,
Charts, Bulletin Boards, Indices, Watchlists, Portfolio, Market News, Research
or see our Premium Services including Level 2, Terminal and much more.
Follow us on Twitter